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Abstract  
 
We report proteomic analyses that establish the effect of cytoplasmic prion [PSI
+
] on the protein 
complement of yeast mitochondria. A set of 44 yeast mitochondrial proteins whose levels were 
affected by [PSI
+
] was identified by two methods of gel-free and label-free differential proteomics. 
From this set we focused on prohibitins, Phb1 and Phb2, and the mitochondrially synthesized Cox2 
subunit of cytochrome oxidase.  By immunoblotting we confirmed the decreased level of Cox2 and 
reduced mitochondrial localization of the prohibitins in [PSI
+
] cells, which both became partially 
restored by [PSI
+
] curing. The presence of the [PSI
+
] prion also caused premature fragmentation of 
mitochondria, a phenomenon linked to prohibitin depletion in mammalian cells. By fractionation of 
cellular extracts we demonstrated a [PSI
+
]-dependent increased of the proportion of prohibitins in 
the high molecular weight fraction of aggregated proteins. We propose that the presence of the yeast 
prion causes newly synthesized prohibitins to aggregate in the cytosol, and therefore reduces their 
levels in mitochondria, which in turn reduces the stability of Cox2 and possibly of other proteins, 
not investigated here in detail. 
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1. Introduction 
 
Prions are a unique class of infectious agents whose infectivity relies solely on protein. In 
mammals, they cause fatal neurodegenerative diseases such as Creutzfeldt-Jacob disease in man, 
ovine scrapie and bovine spongiform encephalopathy. All these diseases are related to the PrP 
protein whose conformationally altered form (PrP
Sc
) is able to convert the normal host-encoded 
protein (PrP
C
) into an altered prion form. While only one prion protein is known in mammals, the 
mammalian prions appear to represent just part of a much wider phenomenon, also being found in 
lower eukaryotes. In contrast to mammalian prions, those of lower eukaryotes cause non-
chromosomal inheritance of phenotypic traits (reviewed in [1, 2]). From a structural point of view 
prion proteins, and also yeast prions, possess the ability for spontaneous assembly in an 
autocatalytic process into amyloid [3]. Amyloid-type protein aggregates are characterized by the so-
called “cross-beta” alignment of monomeric units, and yeast prions are no exception [4-6]. Yeast 
prions may be used as a convenient model for elucidation of the factors interacting with human 
prions and other amyloids. 
The yeast prion [PSI
+
] is a self-perpetuating conformation of the translation termination 
factor Sup35 (eRF3) (for a review, see [7]). Sup35 forms a complex with Sup45/eRF1 that is 
involved in recognizing termination codons and releasing the translation product from the ribosome 
[8, 9]. The prion state of Sup35 can be propagated for many cellular generations in a stable way. 
This may be observed as the nonsense suppressor phenotype, [PSI
+
], which reflects the reduced 
function of Sup35 due to aggregation of its prion form. It is noteworthy that [PSI
+
] can also induce 
read-through of stop codons at the end of open reading frames of yeast wild type genes, which 
could be the reason for the variety of weak phenotypes manifested by [PSI
+
] strains [10].  
The study of the yeast prion [PSI
+
] resulted in the first evidence connecting prions with a 
cellular stress defense system [11]. Various chaperones can either promote prion propagation and 
generation or eliminate it from the cell. [PSI
+
] and other yeast prions, [URE3] and [PIN
+
], are 
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maintained only in the presence of the chaperone Hsp104 (for a review see [1]). It has been shown 
that increasing or decreasing the level of Hsp104 results in the loss of [PSI
+
]. The stress-inducible 
Ssa proteins generally help prions to propagate, while constitutively expressed proteins of the Ssb 
family are prion antagonists [12-14]. Hsp40 co-chaperones, Ydj1 and Sis1, as well as Sse1, a 
nucleotide exchange factor for Hsp70, exhibit various effects on yeast prions [15, 16]. Although 
numerous previous attempts have failed, most recent papers proved a physical interaction between 
Sup35 and Hsp104 in vitro and suggest its existence in vivo]. Sup35, preferentially in the [PSI
+
] 
state interacts also directly with some other chaperones [17-19]. 
Our previous work indicated a connection between the yeast prion [PSI
+
] and mitochondria. 
Although the [PSI
+
] wild type strain exhibited no difference in respiration competence compared to 
the corresponding [psi
-
], in combination with a mutant Nam9-1 protein of the mitochondrial 
ribosome [PSI
+
] caused a lack of respiration [20]. This effect of [PSI
+
] in the nam9-1 mutant 
correlated with decreased levels of the mitochondrially encoded Cox2 and other subunits of 
cytochrome oxidase, a hetero-oligomeric protein complex located in the inner mitochondrial 
membrane. The respiratory deficiency in the nam9-1 mutant was cured by overproduction or 
inactivation of Hsp104, exactly the same conditions that eliminate [PSI
+
]. Another prion, [PIN
+
], 
which often coexists with [PSI
+
], was not known during the time of this study and [PIN] status of 
the nam9-1 mutant was not determined. However [PIN
+
] is not cured by overproduced Hsp104, 
therefore [PIN
+
] could be excluded as a potential reason of respiratory deficiency in nam9-1. We 
then considered how the presence of [PSI
+
] aggregates interferes with mitochondrial function. Since 
it had been reported that proteins can become trapped in [PSI
+
] aggregates [21], we expected that 
recruitment of proteins interacting with the mitochondrial translation machinery by [PSI
+
] 
aggregates might account for the respiratory deficiency in the presence of Nam9-1. It was also 
conceivable that [PSI
+
] aggregates might change the level of cytosolic chaperones required for the 
translocation of proteins to mitochondria, which in turn might alter the relative level of one or more 
components of the mitochondrial translation system. Finally, one could expect that [PSI
+
]-induced 
5 
 
stop codon readthrough generates one or more novel mitochondrial proteins bearing an extra C-
terminal domain and causing repiratory deficiency in combination with Nam9-1. In this context it 
was of interest to perform a quantitative comparison of mitochondrial proteins in isogenic [PSI
+
] 
and [psi
-
] strains.  
The mitochondrial proteome, being a relatively small, but still complicated protein network, 
has already been studied in considerable detail. Several reports describing the set of mitochondrial 
proteins from yeast and mammals have been published [22-35]. In addition, different genomic 
approaches have been integrated to define a complete protein repertoire of the organelle using yeast 
mitochondria as a model [24]. Moreover, a comprehensive network of protein interactions in a 
mitochondrial system, as part of the yeast interactome, has been built. This map of the 
interrelationships among mitochondrial proteins greatly facilitates the interpretation of the results of 
global analyses of the yeast mitochondrial proteome upon perturbation [36]. 
Here, global proteomic analysis was applied to search for the differences in the levels of 
mitochondrial proteins in two isogenic yeast [psi
-
] and [PSI
+
] strains. This analysis identified 44 
candidate proteins of which the levels were significantly changed. The list includes, for instance, 
Cox2 protein, which was found in a previous study to be downregulated in the presence of [PSI
+
]. 
Two other proteins from the list, prohibitins Phb1 and Phb2, immediate neighbors of Cox2 in the 
yeast mitochondrial interactome net, were selected for further analysis. Their downregulation in the 
presence of the prion [PSI
+
] and their regulation by Hsp104 level was confirmed by Western blot 
analysis. Furthermore, fractionation of yeast cell lysates demonstrated [PSI
+
]-dependent enrichment 
of prohibitins in the aggregated protein fraction. Our results indicate that depletion of prohibitins 
can provide the rationale for the mitochondrial functional defects observed earlier in [PSI
+
] yeast 
cells. 
 
2. Materials and Methods 
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2.1. Yeast strains and growth conditions 
Saccharomyces cerevisiae strain GT197 (MAT ade1-14 trp1- ura3-52 leu2-3,112 lys2 his3), 
referred to as [psi-] and the isogenic [PSI
+
] strain GT81-1D [37] were used throughout this study. 
In the experiment shown in Fig. 2B derivatives of MB43-nam9-1 (MATa ura3 his3, his4C nam9-1 
[PSI
+
]) [20] were used. In order to prevent glucose repression yeast cells were grown in YPE 
medium (1% yeast extract, 2% bactopeptone, 2% ethanol) or in low-glucose medium (1% yeast 
extract, 2% bactopeptone, 0.5% glucose). Cultures were harvested at an optical density of 600 nm 
(OD600) of 1.5 to 1.7, which corresponded, in the case of the low-glucose medium, to a point of 
glucose exhaustion, as determined with Glucostix (Bayer). 
To assess mitochondria by fluorescence, GT197 [psi-] and the isogenic [PSI
+
] GT81-1D strains 
were transformed with pYX323-mtGFP plasmid (2 μ, TRP1) encoding green florescence protein 
(GFP) with a mitochondrial localization sequence [38] .Transformants were grown in minimal SC-
trp medium (0.67% yeast nitrogen base, 2% glucose) supplemented with all amino acids except 
tryptophan. Cells were harvested at OD600 = 1.2.  Neither [psi-] nor the [PSI
+
] strain has a tendency 
to become rho
-
.  
2.2. Isolation of mitochondria 
Isolation of mitochondria was accomplished by differential centrifugation according to [39]. Crude 
mitochondria (protein concentration of 5 mg/ml) were suspended in SEM buffer (250 mM sucrose, 
1 mM EDTA, 10 mM MOPS, pH 7.2) ensuring proper osmotic pressure for maintenance of 
organelle integrity and prevention of its decomposition. The suspension of crude mitochondria was 
loaded onto a three-step sucrose gradient composed of 1.5 ml 60%, 4 ml 32%, 1.5 ml 23% and 1.5 
ml 15% sucrose in EM-buffer (1 mM EDTA, 10 mM MOPS, pH 7.2) and centrifuged for 1 h at 134 
000 x g, yielding highly pure mitochondria at the 60/32% sucrose interface. The sucrose gradient 
step was performed twice. 
2.3. Differential proteomics experiments 
Two methods were used for identification of proteins differentially populated in the two [psi
-
] and 
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[PSI
+
] strains analyzed. Their detailed description is given in the Supporting Material and Method 
Section. In brief, in the first method, further referred to as FTICR, the protein ratios were measured 
by comparing the amplitudes of their corresponding peptide signals in the MS spectra obtained 
from a mitochondrial proteome tryptic peptide mixture in LC-MS experiments using an LTQ 
FTICR (Thermo) mass spectrometer. In the second method, further referred to as WPES, a 
commercially available Waters Protein Expression System, designed to carry out differential 
proteomics experiments, was used to extract differentially populated proteins. The final selection of 
mitochondrial proteins sensitive to the presence of the cytoplasmic prion [PSI
+
] was based on 
statistical validation of the results of replicate experiments. 
2.4. Peptide isoelectrofocusing 
Peptide isoelectrofocusing was carried out as described previously [40] with a minor change to the 
protocol, as follows: 100 μg of proteins in 100 μl of 100 mM ammonium bicarbonate pH 8.5 was 
denatured for 5 min  at 98 °C and cooled on ice. Ten microliters of modified sequencing grade 
trypsin (Promega), 100 ng/μl, was added and the samples were incubated o/n at 37 °C. The protein 
digest was dried in a speed-vac and suspended in 340 μl of sample buffer (7 M urea, 2 M thiourea, 
2% Chaps, 0.5% β-mercaptoethanol, 0.006% IPG buffer pH 3.5–5.0 (Amersham). To remove 
insoluble material centrifugation at 15000 x g was performed for 15 min and supernatant was used 
for overnight passive rehydration of an 18 cm strip of the gel (pH 3.5–4.5) in IPG buffer. IEF was 
performed on a Multiphor II electrophoresis system (Amersham) using a three-step gradient 
program as follows: step 1: 500 V, 2 mA, 2 W, 1 h; step 2: 1000 V, 2 mA, 2 W, 2 h; step 3: 3500 V, 
2 mA, 4 W, 45 h. 
 Following IEF, the strip was cut into ten pieces and peptides were eluted three times with 100 μl 
0.1% TFA, 2% acetonitrile. Pooled fractions were filtered through a 50 kDa cut-off cellulose 
membrane (Millipore) and concentrated on a speed-vac. Qualitative analysis (protein identification) 
was carried out using merged datasets obtained for each of the ten pieces of the IPG strip, as 
described in Supporting Material Section S1 for the LTQ-FTICR qualitative analysis step.  
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2.5. Fractionation of yeast cell lysates 
For the experiment presented in Fig. 2C, total cellular protein was extracted by alkaline lysis as 
described previously [41]. For the fractionation of aggregates (experiment presented in Fig. 3), cells 
were lysed by vortexing with glass beads in buffer A (25
 
mM Tris-HCl, pH 7.5, 50 mM KCl, 
10 mM MgCl2, 1 mM EDTA, 2% glycerol) along with 1 mM PMSF, 2 µg/ml aprotinin, 1 µg/ml 
pepstatin
 
A, 0.5 µg/ml leupeptin, 2.5 µg/ml anti-pain, 0.5 µg/ml TLCK, 0.5
 
µg/ml TPCK, 0.1 mM 
benzamidine and 0.1 mM sodium metabisulfite. Cell debris and mitochondria were removed by 
centrifugation at 15, 000  g for 10 min. Obtained supernatants were treated with RNase A 
(400 µg/ml) to disrupt polyribosomes. Extracts were then subjected to centrifugation through a 
sucrose cushion (1 ml of 30% sucrose in buffer A) in an SW50 rotor at 45 000 r.p.m. for 30 min at 4 
°C. The resulting supernatants, intermediate fractions and pellets were analyzed by Western 
blotting. 
2.6. Western blotting  
For immunoblotting, protein extracts were separated by SDS-PAGE gels and transferred 
electrophoretically onto a nitrocellulose membrane (Millipore). After immunodecoration with the 
desired primary antibody, membranes were incubated with anti-rabbit or anti-mouse horseradish 
peroxidase-conjugated secondary antibody. Reaction with Immobilon Western Chemiluminescent 
HRP Substrate (Millipore) was performed according to the manufacturer’s instructions and light 
emitted was subsequently captured on X-ray film (Amersham). Films were quantified using 
ImageQuant (GE Healthcare Life Sciences) with local average background correction. 
2.7. Confocal microscopy 
Cells were washed with water, plated on microscope glass slides and subjected to confocal laser 
scanning microscopy. An Eclipse TE2000-E microscope (Nikon), equipped with a Plan Apo 60X oil 
objective was used. mtGFP was excited with an Argon-Ion laser at 488 nm, and emission was 
detected at 515/30 nm. Images were collected with the EZ-C1 Confocal v. 3.6 program (Nikon) and 
then processed with EZ-C1 Viewer v. 3.6 (Nikon) and Adobe Photoshop 8.0. 
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3. Results  
3.1. Analysis of mitochondrial proteome 
Mitochondria were isolated from Saccharomyces cerevisiae prion-free strain GT197 referred to as 
[psi-] and the isogenic strain GT81-1D containing [PSI
+
] referred to as [PSI
+
]. Both [psi-] and 
[PSI
+
] strains are respiratory competent and mitochondria were isolated using a standard 
fractionation procedure. The identification of mitochondrial proteins derived from [PSI
+
] and [psi
-
] 
strains was carried out by several rounds of LC-MS-MS/MS (Liquid Chromatography coupled to 
Mass Spectrometry in data-dependent switch to fragmentation mode) experiments using an LTQ 
FTICR spectrometer, as described in the Supporting Material and Method Section. The obtained list 
of 1275 mitochondrial proteins was compared with the mitochondrial proteome characterized 
previously by other authors [22-28], (Supporting Material Table S1). In all, 972 (76%) proteins 
were indicated as mitochondrial in earlier either MS-based or “in silico” studies (Supporting 
Material Fig. S1). We identified 34 mitochondrial proteins that are present in the MREF 
mitochondrial database [42] although, to our knowledge, they have not been identified previously 
by MS-based studies on the S. cerevisiae mitochondrial proteome[22-27], Prokish-unpublished 
dataset, [28] (Supporting Material Table S2). Our list of proteins contains representatives of 45 out 
of the 46 major functional modules of the yeast mitochondrial interactome constructed by Perocchi 
and co-workers [36] (Supporting Material Fig. S2 and Table S3).  
Similarly to other proteomic studies, the number of detected proteins was higher than the 
number of proteins in the accepted mitochondrial reference set. Two factors may explain this 
apparent inconsistency. First, it is possible that the mitochondrial reference set is not yet complete 
and that the detected proteins are new mitochondrial proteins, or second, our preparation procedure 
did not fully eliminate non-mitochondrial proteins. It has to be noted, however, that the main aim of 
our experiment was to identify differential proteins between [PSI
+
] and [psi
-
] strains. Therefore the 
possible presence of non-mitochondrial proteins does not compromise the validity of our results. 
In conclusion, our identification of mitochondrial proteins in [PSI
+
] and [psi
-
] strains, 
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proved to be of comparable quality to previous protein identification efforts. Thus we can state that 
the set of mitochondrial proteins considered in the differential analysis is reasonably complete and 
representative. 
3.2. Prohibitins and Cox2 among proteins identified by differential proteomics of the 
mitochondria of [PSI
+
] and [psi
-
] strains  
To obtain a list of proteins of which the levels are affected by the presence of prion [PSI
+
], two 
independent methods of differential proteomics, named FTICR and WPES, were used and each was 
repeated three times (see the Supporting Material and Method Section for details of the methods, 
the statistical analysis and hit acceptance criteria). Figure 1 shows the comparison of protein level 
as the [PSI
+
]/[psi
-
] ratios. Forty-one of these proteins showed the same direction of expression 
changes in both experiments (Supporting Material Table S4). This fairly large number of detected 
differential proteins indicates that the presence of prion [PSI
+
] in the yeast cytoplasm induces a 
complex response in mitochondria. 
 [PSI
+
]-dependent proteins identified in our experiment belong to several
 
annotation 
categories. [PSI
+
] mitochondria showed decreased levels of several subunits of respiratory 
complexes, such as Cox2, Atp1, Atp2, Atp3 and Sdh1. There were also decreased levels of some 
enzymes of isocitrate metabolism. In addition we observed marked changes
 
in the levels of some 
chaperones and receptors involved in mitochondrial protein import, such as Tom40, Tim13 and 
Ssc1. The identification of these proteins as affected by [PSI
+
] links the prion with the 
reorganization of the mitochondrial import apparatus. Interestingly, both prohibitins Phb1 and Phb2 
were also downregulated in the [PSI
+
] mitochondria. Phb1 and Phb2 prohibitins act as membrane-
bound chaperones involved in the stabilization of mitochondrial translation products including 
Cox2 [43-45]. Because of this relation, Cox2 and prohibitins are immediate neighbors in the yeast 
mitochondrial interactome [46] (Supporting Material Fig. S3). Moreover, Cox2 is known to be 
involved in prion-dependent phenomena in yeast [20]. Encouraged by the known functional links 
between Cox2, Phb1 and Phb2, we focused our attention on these three proteins.  
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Two independent proteomic methods showed that Cox2 and the two prohibitins, Phb1 and 
Phb2, are less abundant in mitochondria in [PSI
+
] cells. In the [PSI
+
] strain the Cox2 level was 
decreased over 3.5 fold (p=0.0048). The [PSI
+
]/[psi
-
] ratio for Cox2 was estimated on the basis of 
eleven peptides in FTICR and eight in the WPES experiment, respectively. Phb1 was decreased 1.9 
fold (p=0.058) as estimated on the basis of seven peptides in FTICR and ten in WPES. For Phb2 17 
peptides in FTICR, and 11 in WPES were used for ratio calculation giving a 1.3 fold decrease in 
[PSI
+
] cells (p=0.11). The signal amplitude values of Phb1, Phb2 and Cox2 peptides are presented 
in the Supporting Material, Fig. S4. 
3.3. Reduced levels of Cox2 and prohibitins in [PSI
+
] mitochondria detected by 
immunoblotting 
To provide independent confirmation of the MS differential analyses, mitochondria isolated 
from [psi
-
] and [PSI
+
] cells were analyzed by Western blotting with specific antibodies. The results 
(Fig. 2A) reproducibly confirm that the presence of [PSI
+
] reduces the levels of mitochondrial 
Cox2, Phb1 and Phb2.  We next investigated whether the amount of mitochondrial prohibitins was 
affected by curing of cells from [PSI
+
]. Yeast may be cured from the [PSI
+
] prion by overexpression 
or deletion of the gene encoding the Hsp104 chaperone [1, 2, 11]. We took advantage of two 
observations: first, that [PSI
+
] curing by Hsp104 stabilized Cox2 in the MB43-nam9-1 strain [20] 
and second, that prohibitins are known to stabilize mitochondrially synthesized proteins, including 
Cox2 [43-45]. Thus we considered the possibility that [PSI
+
] curing may increase the levels of 
prohibitins in mitochondria and that this effect is a prerequisite for Cox2 stabilization. Indeed, the 
Western blot analysis of the mitochondria (Fig. 2B) showed that deletion or overexpression of the 
HSP104 gene in [PSI
+
] MB43-nam9-1 cells resulted in an increase in Phb1 and Phb2 levels. These 
results clearly indicate a link between curing of the [PSI
+
] prion and the levels of prohibitins and 
Cox2 in mitochondria. 
For quantification, the intensities of bands were measured using nuclear-encoded mitochondrial 
malate dehydrogenase Mdh1 as an internal control. The results of MS and Western analyses 
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comparing the effect of [PSI
+
] were consistent, even in cells of different genetic background (Table 
1). Cox2 is a mitochondrially synthesized protein, the stability of which is known to be prion-
dependent [20], and our work confirmed this. In contrast, prohibitins are synthesized in the 
cytoplasm and then imported to mitochondria. The observed decrease in the amount of 
mitochondrial prohibitins might result from their lower synthesis in [PSI
+
] cells. Interestingly, 
Western blot analysis of total yeast extracts shows a decreased amount of Cox2 in the [PSI
+
] strain, 
but does not reveal differences between the levels of prohibitins in the [psi
-
] and [PSI
+
] strains (Fig. 
2C). This suggests that the observed depletion of mitochondrial prohibitins was due to their 
inefficient import into the mitochondria in cells with the [PSI
+
] prion.  
 3.4. [PSI
+
] causes enrichment of prohibitins in the cellular aggregates fraction  
[PSI
+
] is the prion conformation of the Sup35 protein, a cytoplasmic translation termination 
factor. [PSI
+
] affected the levels of mitochondrial prohibitins but not their total amount in the yeast 
cell (Fig. 2), suggesting a defect in intracellular distribution. This might be due to a physical 
interaction of prohibitins with Sup35 aggregates occurring in the cytoplasm and affecting their 
import to mitochondria.  
It has previously been shown that Sup35 forms high-molecular-weight aggregates in [PSI
+
] 
cells, co-sedimenting with the heavy polyribosomal fraction and even larger structures [47]. Thus 
distribution of prohibitins between the soluble and aggregated fractions could be influenced by the 
[PSI] status of the cells. To check this, extracts of isogenic [psi
-
] and [PSI
+
] strains were prepared 
using the clarifying spin to eliminate the remaining mitochondria (see Materials and Methods). 
Extracts were fractionated by centrifugation through a sucrose cushion, and the fractions were 
analyzed by immunoblotting using antibodies against Sup35, Phb1 and Phb2. In agreement with 
previous results [47], after centrifugation most of the Sup35 protein was found in the pellet fraction 
in the [PSI
+
] strain, whereas in the [psi
-
] strain Sup35 remained in the supernatant (Fig. 3, upper 
panel). Prohibitins were detected almost exclusively in the pellet fraction, although some remained 
in the sucrose cushion. The presence of prohibitins in the pellet cannot be attributed to the residual 
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presence of contaminating mitochondria, as their absence was carefully controlled by the absence of 
the other mitochondrial protein, aconitase (Aco1) in the pellet. Interestingly, both Phb1 and Phb2 
were relatively more abundant in the pellet fraction from the [PSI
+
] strain than in the respective 
fraction from the [psi
-
] strain (Fig. 3, lower panel). This suggests that prohibitins are partially 
trapped by cytoplasmic [PSI
+
] prion aggregates, which in turn should decrease their availability for 
import into the mitochondria.  
3.5. [PSI
+
] causes premature fragmentation of mitochondria  
 The yeast mutants with inactive prohibitin showed abnormal mitochondrial morphology and 
defects of mitochondria segregation, especially in old cells [48]. A recent study in mammals 
revealed that prohibitins determine cristae morphogenesis and formation of tubular mitochondrial 
ultrastructures, since 90% of PHB2-deficient mouse cells contained fragmented mitochondria [49]. 
We explored the possibility that [PSI
+
] could indirectly affect fusion of mitochondria in yeast by 
reduction of the levels of mitochondrial prohibitins. To investigate mitochondrial ultrastructure, 
[psi
-
] and [PSI
+
] cells were transformed with pYX323-mtGFP plasmid (2 μ, TRP1) encoding green 
fluorescent protein (GFP) containing a mitochondrial localization signal. To prevent the loss of 
plasmid, cells were cultivated in minimal medium lacking tryptophan. The growth rate was 
controlled by OD measurements, indicating no difference between [psi
-
] and [PSI
+
] strains. Cells 
were harvested at the same point in the late logarithmic phase and examined by confocal 
microscopy. Strikingly, [PSI
+
] cells contained 95% of fragmented mitochondria whereas the 
majority of [psi
-
] cells in the same phase contained regular tubular mitochondrial ultrastructures 
(Fig. 4). This showed premature fragmentation of mitochondria in [PSI
+
] cells, providing a link 
between the presence of cytoplasmic prion [PSI
+
] and defects in mitochondrial fusion, which may 
be caused by reduced prohibitins (see Discussion).  
 
 
 
 
4. Discussion 
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Several years ago it was reported that stability of the mitochondria-encoded respiratory 
chain subunit Cox2 in a mitochondrial ribosomal mutant nam9-1 depends on the yeast prion [PSI
+
] 
[20]. This observation is striking because the prion is located in the cytosol, whereas the synthesis 
and assembly of Cox2 takes place in mitochondria. In order to obtain a better insight into this 
unexpected relation, we used a proteomics approach to search for differences in the levels of 
mitochondrial proteins in prion-positive [PSI
+
] and prion-negative [psi
-
] cells. We obtained a list of 
44 mitochondrial proteins showing altered abundance depending on the presence of [PSI
+
]. Among 
those were Cox2 and several other subunits of cytochrome oxidase and mitochondrial ATPase. 
Importantly, the levels of the two prohibitins, Phb1 and Phb2, were also reduced in mitochondria of 
[PSI
+
] cells.  
Prohibitins are evolutionarily conserved eukaryotic proteins that assemble in a large ring 
complex bound to inner mitochondrial membrane [51-53].. Earlier findings in yeast identified 
prohibitins in assemblies with ATP-dependent protease m-AAA involved in chaperoning and 
turnover of mitochondrial inner membrane proteins [43, 44]. Yeast mutants lacking functional 
prohibitins show accelerated proteolysis by m-AAA protease suggesting a regulatory role of 
prohibitins in the quality control of proteins in inner membrane [45, 50]. Phb1/2 complex, 
reminiscent of Hsp60-like chaperones, is proposed to act as a novel type of membrane-associated 
chaperone/holdase involved in higher order organization of respiratory chain complexes [51-53]. 
Using molecular methods provide evidence that Phb1, Phb2 and Cox2 are less abundant in 
mitochondria in [PSI
+
] cells, thus confirming proteomic results and suggesting lowered 
mitochondrial prohibitins as a potential reason of Cox2 destabilization.  
Another function of prohibitins described recently in mammals is the processing of the 
dynamin-like GTPase OPA1, an essential component of the mitochondrial fusion machinery [49]. 
OPA1 is a homologue of yeast Mgm1 protein also involved in mitochondria fusion [54]. Both OPA1 
and Mgm1 exist in forms of different lengths and their function is regulated by proteolytic cleavage 
[55, 56] Only a long form of OPA1 (L-OPA1) is fusion competent [55], and maintenance of this 
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form requires prohibitins [49]. Depletion of prohibitins induces L-OPA1-dependent fragmentation 
of mitochondria and apoptosis. The mechanism underlying the selective loss of L-OPA1 in the 
absence of prohibitins remains to be elucidated [57].  
Here we detected [PSI
+
]-dependent premature fragmentation of yeast mitochondria in post-
exponential growth phase. It is currently unknown whether the low level of mitochondrial prohibitins 
in [PSI
+
] cells can provide the rationale for the observed negative effect on mitochondrial fusion. 
One interesting hypothesis is that depletion of prohibitins could contribute to the defect in the 
function of Mgm1, the OPA1 homologue, in the fusion of yeast mitochondria. Although Mgm1 
processing is not strictly required for mitochondrial fusion [58], the balanced formation or regulated 
inter-conversion of the two isoforms of Mgm1 appear crucial [59]. Characterization of the effect of 
prohibitins on Mgm1 requires further study. Among the other mitochondrial proteins found to be 
affected by [PSI
+
] in this work, the presence of Hsp78 is remarkable, because this chaperone 
functions in restoration of the mitochondrial network following heat stress [60].  
Although the overall level of expression of prohibitins is the same in the [PSI
+
] and [psi
-
] 
strains, the PSI status affects their distribution within the cell. We were interested in why the 
mitochondrial localization of prohibitins was reduced by the [PSI
+
] prion state. Fractionation of 
mitochondria-free lysates for soluble and aggregate parts showed enrichment of prohibitins in the 
aggregate fraction in [PSI
+
] cells. This result suggests some interaction of Phb1/Phb2 with [PSI
+
] 
possibly leading to sequestration of prohibitins by prion aggregates. The effect of [PSI
+
] on 
sequestering of another cytoplasmic protein, translation termination factor Sup45, has been studied 
in the past, but the results were controversial. Sup45 was reported to be present in [PSI
+
] aggregates 
in some [21, 61] but not other studies [62] and a decisive model of Sup45 sequestering is lacking. 
Similarly, further experiments are required to demonstrate and characterize a specific interaction of 
prohibitins with [PSI
+
] aggregates. Here we just propose that the newly synthesized prohibitins are 
titrated by [PSI
+
] aggregates in the cytosol before they reach mitochondrial location and therefore 
their level in mitochondria is lowered, which in turn reduces the stability of Cox2. Moreover, we 
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believe that prohibitins are not the only component mediating the effect of the [PSI
+
] prion on 
mitochondrial function and the roles of other mitochondrial proteins identified by our proteomic 
study is worth to study as well.  
A different scenario may be proposed of how presence of [PSI
+
] aggregates interferes with 
mitochondrial function. Inefficient termination in cells containing [PSI
+
] potentially allows for 
readthrough of stop codons nuclear mRNAs. Leakiness of stop codons is considered to be the 
reason for a variety a weak phenotypes manifested by [PSI
+
] strains [10]. Nuclear-encoded 
mitochondrial proteins might be expressed in a C-terminally extended version(s) when low levels of 
functional Sup35 allow readthrough of nonsense codons. However, in this and other published 
studies no experimental evidence of C-terminally extended proteins in [PSI
+
] mitochondria has 
been found.  
The overall data presented here support the model that in S. cerevisiae the prion [PSI
+
] 
interacts with prohibitins and possibly other proteins in the cytosol and thereby alters their 
distribution to mitochondria. Thus the hidden phenotypic variation generated by [PSI
+
] may result 
from subtle alteration in sorting of particular proteins between cellular compartments. It is possible 
that some of the [PSI
+
] manifestations can be related to the ability of Sup35 prion aggregates to 
titrate host proteins with important functions though this suggestion has never been supported. 
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Figure Legends 
Fig. 1 . Proteins showing [PSI
+
]-dependent abundance in yeast mitochondria. The [PSI
+
]/[psi
-
] 
ratios of differential proteins (log scale) detected by the two independent differential proteomic 
methods: FTICR and WPES (see text). The ratio obtained for each protein with the FTICR method 
is shown as a red bar and with WPES as a black bar, and the corresponding protein name 
abbreviation is marked along the upper horizontal axis. For the majority of proteins (41 out of 44) 
both methods gave the same direction of change i.e. up- or downregulation, however, the degree of 
change was often substantially different. Note the Phb1, Phb2 and Cox2 proteins (marked in green) 
downregulated in [PSI
+
], as described in detail in the text. 
Fig. 2.  
[PSI
+
] decreases amounts of Phb1, Phb2 and Cox2 in mitochondria.  
Western blot analysis of Cox2, Phb1 and Phb2 levels in mitochondrial (A, B) and total protein 
extracts (C) prepared by alkaline lysis. Proteins were isolated from isogenic [psi
-
] and [PSI
+
] strains 
GT197 and GT81-1D (A, C) or isogenic derivatives of MB43-nam9-1 strain cured from [PSI
+
] by 
deletion [] or overexpression [↑] of the HSP104 gene (B). The levels of Hsp104 were determined 
in the total extracts. Mitochondrial malate dehydrogenase (Mdh1) was used as a loading control.  
.  
Fig. 3. Abundance of prohibitins in cellular aggregates depends on the [PSI] state of the cell. 
 Lysates of [psi
-
] and [PSI
+
] strains (GT197 and GT81-1D) were prepared as described in the 
Materials and Methods and were fractionated by centrifugation through a sucrose cushion. The 
distribution of Phb1, Phb2 and Sup35 between the supernatant soluble fraction, sucrose layer and 
high molecular structures in the pellet was determined by immunoblotting. To confirm that other 
mitochondrial proteins are not present in the pellet, the blot was also decorated with an antibody 
specific for aconitase Aco1, the protein imported to mitochondria from the cytoplasm. The gel was 
loaded using 20 μg of protein per lane for the supernatant and sucrose fractions and 5 μg of protein 
per lane for the pellet fraction.  
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Fig. 4. Fragmentation of mitochondria in prohibitin-deficient [PSI
+
] cells.  
[psi
-
] and [PSI
+
] strains (GT197 and GT81-1D) were transformed with pYX323-mtGFP plasmid 
encoding green fluorescence protein (GFP) with a mitochondrial localization sequence and 
analyzed by confocal laser scanning microscopy. Reconstruction of the mitochondrial network was 
done from about ten confocal sections with intervals of 0.5 m and 1024 x 1024 resolution. The 
images presented are representative for [psi
-
] and [PSI
+
] cells. More than 400 cells were scored per 
experiment. The percentage of cells with tubular mitochondria is indicated.  
 
 
 
Table Legends 
Table 1  
 Levels of Phb1, Phb2 and Cox2 in [PSI
+
] versus [psi
-
] mitochondria. 
[PSI
+
]/[psi
-
] protein ratios were measured by densitometry of Western blots and by differential 
proteomics. 
In order to determine the relative amount of proteins in [PSI
+
] and [psi
-
] strains by immunoblotting, 
the amount of each protein present in [PSI
+
], corrected by the loading control, was set to 1. Column 
1 represents the quantified results of immunoblotting analysis of Phb1, Phb2 and Cox2 in 
mitochondria from [PSI
+
] and [psi
-
] strains GT197 and GT81-1D (Fig. 2A). Columns 2 and 3 show 
the quantified results of the immunoblotting analysis of Phb1 and Phb2 in mitochondria from 
different pairs of isogenic [PSI
+
] and [psi
-
] strains in the genetic background of MB43-nam9-1:: 
[PSI
+
] and its [psi
-
] derivative derived by deletion (column 2) or overexpression (clolumn 3)  of the 
gene encoding Hsp104 chaperone (Fig. 2C). The complex effect of Hsp104 on Cox2 levels in 
[PSI
+
] cells was determined previously [20] 
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[PSI
+
]/[psi
-
] protein ratios for Phb1, Phb2 and Cox2 were determined independently by using two 
MS-based methods, FTICR and WPES, as described in the text and presented in the Supporting 
Material (Table S4, Fig. S4). Of note is the consistency between the numbers obtained by each 
method. 
Table 1. 
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Abstract  
 
We report proteomic analyses that establish the effect of cytoplasmic prion [PSI
+
] on the protein 
complement of yeast mitochondria. A set of 44 yeast mitochondrial proteins whose levels were 
affected by [PSI
+
] was identified by two methods of gel-free and label-free differential proteomics. 
From this set we focused on prohibitins, Phb1 and Phb2, and the mitochondrially synthesized Cox2 
subunit of cytochrome oxidase.  By immunoblotting we confirmed the decreased level of Cox2 and 
reduced mitochondrial localization of the prohibitins in [PSI
+
] cells, which both became partially 
restored by [PSI
+
] curing. The presence of the [PSI
+
] prion also caused premature fragmentation of 
mitochondria, a phenomenon linked to prohibitin depletion in mammalian cells. By fractionation of 
cellular extracts we demonstrated a [PSI
+
]-dependent increased of the proportion of prohibitins in 
the high molecular weight fraction of aggregated proteins. We propose that the presence of the yeast 
prion causes newly synthesized prohibitins to aggregate in the cytosol, and therefore reduces their 
levels in mitochondria, which in turn reduces the stability of Cox2 and possibly of other proteins, 
not investigated here in detail. 
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1. Introduction 
 
Prions are a unique class of infectious agents whose infectivity relies solely on protein. In 
mammals, they cause fatal neurodegenerative diseases such as Creutzfeldt-Jacob disease in man, 
ovine scrapie and bovine spongiform encephalopathy. All these diseases are related to the PrP 
protein whose conformationally altered form (PrP
Sc
) is able to convert the normal host-encoded 
protein (PrP
C
) into an altered prion form. While only one prion protein is known in mammals, the 
mammalian prions appear to represent just part of a much wider phenomenon, also being found in 
lower eukaryotes. In contrast to mammalian prions, those of lower eukaryotes cause non-
chromosomal inheritance of phenotypic traits (reviewed in [1, 2]). From a structural point of view 
prion proteins, and also yeast prions, possess the ability for spontaneous assembly in an 
autocatalytic process into amyloid [3]. Amyloid-type protein aggregates are characterized by the so-
called “cross-beta” alignment of monomeric units, and yeast prions are no exception [4-6]. Yeast 
prions may be used as a convenient model for elucidation of the factors interacting with human 
prions and other amyloids. 
The yeast prion [PSI
+
] is a self-perpetuating conformation of the translation termination 
factor Sup35 (eRF3) (for a review, see [7]). Sup35 forms a complex with Sup45/eRF1 that is 
involved in recognizing termination codons and releasing the translation product from the ribosome 
[8, 9]. The prion state of Sup35 can be propagated for many cellular generations in a stable way. 
This may be observed as the nonsense suppressor phenotype, [PSI
+
], which reflects the reduced 
function of Sup35 due to aggregation of its prion form. It is noteworthy that [PSI
+
] can also induce 
read-through of stop codons at the end of open reading frames of yeast wild type genes, which 
could be the reason for the variety of weak phenotypes manifested by [PSI
+
] strains [10].  
The study of the yeast prion [PSI
+
] resulted in the first evidence connecting prions with a 
cellular stress defense system [11]. Various chaperones can either promote prion propagation and 
generation or eliminate it from the cell. [PSI
+
] and other yeast prions, [URE3] and [PIN
+
], are 
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maintained only in the presence of the chaperone Hsp104 (for a review see [1]). It has been shown 
that increasing or decreasing the level of Hsp104 results in the loss of [PSI
+
]. The stress-inducible 
Ssa proteins generally help prions to propagate, while constitutively expressed proteins of the Ssb 
family are prion antagonists [12-14]. Hsp40 co-chaperones, Ydj1 and Sis1, as well as Sse1, a 
nucleotide exchange factor for Hsp70, exhibit various effects on yeast prions [15, 16]. Although 
numerous previous attempts have failed, most recent papers proved a physical interaction between 
Sup35 and Hsp104 in vitro and suggest its existence in vivo]. Sup35, preferentially in the [PSI
+
] 
state interacts also directly with some other chaperones [17-19]. 
Our previous work indicated a connection between the yeast prion [PSI
+
] and mitochondria. 
Although the [PSI
+
] wild type strain exhibited no difference in respiration competence compared to 
the corresponding [psi
-
], in combination with a mutant Nam9-1 protein of the mitochondrial 
ribosome [PSI
+
] caused a lack of respiration [20]. This effect of [PSI
+
] in the nam9-1 mutant 
correlated with decreased levels of the mitochondrially encoded Cox2 and other subunits of 
cytochrome oxidase, a hetero-oligomeric protein complex located in the inner mitochondrial 
membrane. The respiratory deficiency in the nam9-1 mutant was cured by overproduction or 
inactivation of Hsp104, exactly the same conditions that eliminate [PSI
+
]. Another prion, [PIN
+
], 
which often coexists with [PSI
+
], was not known during the time of this study and [PIN] status of 
the nam9-1 mutant was not determined. However [PIN
+
] is not cured by overproduced Hsp104, 
therefore [PIN
+
] could be excluded as a potential reason of respiratory deficiency in nam9-1. We 
then considered how the presence of [PSI
+
] aggregates interferes with mitochondrial function. Since 
it had been reported that proteins can become trapped in [PSI
+
] aggregates [21], we expected that 
recruitment of proteins interacting with the mitochondrial translation machinery by [PSI
+
] 
aggregates might account for the respiratory deficiency in the presence of Nam9-1. It was also 
conceivable that [PSI
+
] aggregates might change the level of cytosolic chaperones required for the 
translocation of proteins to mitochondria, which in turn might alter the relative level of one or more 
components of the mitochondrial translation system. Finally, one could expect that [PSI
+
]-induced 
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stop codon readthrough generates one or more novel mitochondrial proteins bearing an extra C-
terminal domain and causing repiratory deficiency in combination with Nam9-1. In this context it 
was of interest to perform a quantitative comparison of mitochondrial proteins in isogenic [PSI
+
] 
and [psi
-
] strains.  
The mitochondrial proteome, being a relatively small, but still complicated protein network, 
has already been studied in considerable detail. Several reports describing the set of mitochondrial 
proteins from yeast and mammals have been published [22-35]. In addition, different genomic 
approaches have been integrated to define a complete protein repertoire of the organelle using yeast 
mitochondria as a model [24]. Moreover, a comprehensive network of protein interactions in a 
mitochondrial system, as part of the yeast interactome, has been built. This map of the 
interrelationships among mitochondrial proteins greatly facilitates the interpretation of the results of 
global analyses of the yeast mitochondrial proteome upon perturbation [36]. 
Here, global proteomic analysis was applied to search for the differences in the levels of 
mitochondrial proteins in two isogenic yeast [psi
-
] and [PSI
+
] strains. This analysis identified 44 
candidate proteins of which the levels were significantly changed. The list includes, for instance, 
Cox2 protein, which was found in a previous study to be downregulated in the presence of [PSI
+
]. 
Two other proteins from the list, prohibitins Phb1 and Phb2, immediate neighbors of Cox2 in the 
yeast mitochondrial interactome net, were selected for further analysis. Their downregulation in the 
presence of the prion [PSI
+
] and their regulation by Hsp104 level was confirmed by Western blot 
analysis. Furthermore, fractionation of yeast cell lysates demonstrated [PSI
+
]-dependent enrichment 
of prohibitins in the aggregated protein fraction. Our results indicate that depletion of prohibitins 
can provide the rationale for the mitochondrial functional defects observed earlier in [PSI
+
] yeast 
cells. 
 
2. Materials and Methods 
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2.1. Yeast strains and growth conditions 
Saccharomyces cerevisiae strain GT197 (MAT ade1-14 trp1- ura3-52 leu2-3,112 lys2 his3), 
referred to as [psi-] and the isogenic [PSI
+
] strain GT81-1D [37] were used throughout this study. 
In the experiment shown in Fig. 2B derivatives of MB43-nam9-1 (MATa ura3 his3, his4C nam9-1 
[PSI
+
]) [20] were used. In order to prevent glucose repression yeast cells were grown in YPE 
medium (1% yeast extract, 2% bactopeptone, 2% ethanol) or in low-glucose medium (1% yeast 
extract, 2% bactopeptone, 0.5% glucose). Cultures were harvested at an optical density of 600 nm 
(OD600) of 1.5 to 1.7, which corresponded, in the case of the low-glucose medium, to a point of 
glucose exhaustion, as determined with Glucostix (Bayer). 
To assess mitochondria by fluorescence, GT197 [psi-] and the isogenic [PSI
+
] GT81-1D strains 
were transformed with pYX323-mtGFP plasmid (2 μ, TRP1) encoding green florescence protein 
(GFP) with a mitochondrial localization sequence [38] .Transformants were grown in minimal SC-
trp medium (0.67% yeast nitrogen base, 2% glucose) supplemented with all amino acids except 
tryptophan. Cells were harvested at OD600 = 1.2.  Neither [psi-] nor the [PSI
+
] strain has a tendency 
to become rho
-
.  
2.2. Isolation of mitochondria 
Isolation of mitochondria was accomplished by differential centrifugation according to [39]. Crude 
mitochondria (protein concentration of 5 mg/ml) were suspended in SEM buffer (250 mM sucrose, 
1 mM EDTA, 10 mM MOPS, pH 7.2) ensuring proper osmotic pressure for maintenance of 
organelle integrity and prevention of its decomposition. The suspension of crude mitochondria was 
loaded onto a three-step sucrose gradient composed of 1.5 ml 60%, 4 ml 32%, 1.5 ml 23% and 1.5 
ml 15% sucrose in EM-buffer (1 mM EDTA, 10 mM MOPS, pH 7.2) and centrifuged for 1 h at 134 
000 x g, yielding highly pure mitochondria at the 60/32% sucrose interface. The sucrose gradient 
step was performed twice. 
2.3. Differential proteomics experiments 
Two methods were used for identification of proteins differentially populated in the two [psi
-
] and 
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[PSI
+
] strains analyzed. Their detailed description is given in the Supporting Material and Method 
Section. In brief, in the first method, further referred to as FTICR, the protein ratios were measured 
by comparing the amplitudes of their corresponding peptide signals in the MS spectra obtained 
from a mitochondrial proteome tryptic peptide mixture in LC-MS experiments using an LTQ 
FTICR (Thermo) mass spectrometer. In the second method, further referred to as WPES, a 
commercially available Waters Protein Expression System, designed to carry out differential 
proteomics experiments, was used to extract differentially populated proteins. The final selection of 
mitochondrial proteins sensitive to the presence of the cytoplasmic prion [PSI
+
] was based on 
statistical validation of the results of replicate experiments. 
2.4. Peptide isoelectrofocusing 
Peptide isoelectrofocusing was carried out as described previously [40] with a minor change to the 
protocol, as follows: 100 μg of proteins in 100 μl of 100 mM ammonium bicarbonate pH 8.5 was 
denatured for 5 min  at 98 °C and cooled on ice. Ten microliters of modified sequencing grade 
trypsin (Promega), 100 ng/μl, was added and the samples were incubated o/n at 37 °C. The protein 
digest was dried in a speed-vac and suspended in 340 μl of sample buffer (7 M urea, 2 M thiourea, 
2% Chaps, 0.5% β-mercaptoethanol, 0.006% IPG buffer pH 3.5–5.0 (Amersham). To remove 
insoluble material centrifugation at 15000 x g was performed for 15 min and supernatant was used 
for overnight passive rehydration of an 18 cm strip of the gel (pH 3.5–4.5) in IPG buffer. IEF was 
performed on a Multiphor II electrophoresis system (Amersham) using a three-step gradient 
program as follows: step 1: 500 V, 2 mA, 2 W, 1 h; step 2: 1000 V, 2 mA, 2 W, 2 h; step 3: 3500 V, 
2 mA, 4 W, 45 h. 
 Following IEF, the strip was cut into ten pieces and peptides were eluted three times with 100 μl 
0.1% TFA, 2% acetonitrile. Pooled fractions were filtered through a 50 kDa cut-off cellulose 
membrane (Millipore) and concentrated on a speed-vac. Qualitative analysis (protein identification) 
was carried out using merged datasets obtained for each of the ten pieces of the IPG strip, as 
described in Supporting Material Section S1 for the LTQ-FTICR qualitative analysis step.  
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2.5. Fractionation of yeast cell lysates 
For the experiment presented in Fig. 2C, total cellular protein was extracted by alkaline lysis as 
described previously [41]. For the fractionation of aggregates (experiment presented in Fig. 3), cells 
were lysed by vortexing with glass beads in buffer A (25
 
mM Tris-HCl, pH 7.5, 50 mM KCl, 
10 mM MgCl2, 1 mM EDTA, 2% glycerol) along with 1 mM PMSF, 2 µg/ml aprotinin, 1 µg/ml 
pepstatin
 
A, 0.5 µg/ml leupeptin, 2.5 µg/ml anti-pain, 0.5 µg/ml TLCK, 0.5
 
µg/ml TPCK, 0.1 mM 
benzamidine and 0.1 mM sodium metabisulfite. Cell debris and mitochondria were removed by 
centrifugation at 15, 000  g for 10 min. Obtained supernatants were treated with RNase A 
(400 µg/ml) to disrupt polyribosomes. Extracts were then subjected to centrifugation through a 
sucrose cushion (1 ml of 30% sucrose in buffer A) in an SW50 rotor at 45 000 r.p.m. for 30 min at 4 
°C. The resulting supernatants, intermediate fractions and pellets were analyzed by Western 
blotting. 
2.6. Western blotting  
For immunoblotting, protein extracts were separated by SDS-PAGE gels and transferred 
electrophoretically onto a nitrocellulose membrane (Millipore). After immunodecoration with the 
desired primary antibody, membranes were incubated with anti-rabbit or anti-mouse horseradish 
peroxidase-conjugated secondary antibody. Reaction with Immobilon Western Chemiluminescent 
HRP Substrate (Millipore) was performed according to the manufacturer’s instructions and light 
emitted was subsequently captured on X-ray film (Amersham). Films were quantified using 
ImageQuant (GE Healthcare Life Sciences) with local average background correction. 
2.7. Confocal microscopy 
Cells were washed with water, plated on microscope glass slides and subjected to confocal laser 
scanning microscopy. An Eclipse TE2000-E microscope (Nikon), equipped with a Plan Apo 60X oil 
objective was used. mtGFP was excited with an Argon-Ion laser at 488 nm, and emission was 
detected at 515/30 nm. Images were collected with the EZ-C1 Confocal v. 3.6 program (Nikon) and 
then processed with EZ-C1 Viewer v. 3.6 (Nikon) and Adobe Photoshop 8.0. 
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3. Results  
3.1. Analysis of mitochondrial proteome 
Mitochondria were isolated from Saccharomyces cerevisiae prion-free strain GT197 referred to as 
[psi-] and the isogenic strain GT81-1D containing [PSI
+
] referred to as [PSI
+
]. Both [psi-] and 
[PSI
+
] strains are respiratory competent and mitochondria were isolated using a standard 
fractionation procedure. The identification of mitochondrial proteins derived from [PSI
+
] and [psi
-
] 
strains was carried out by several rounds of LC-MS-MS/MS (Liquid Chromatography coupled to 
Mass Spectrometry in data-dependent switch to fragmentation mode) experiments using an LTQ 
FTICR spectrometer, as described in the Supporting Material and Method Section. The obtained list 
of 1275 mitochondrial proteins was compared with the mitochondrial proteome characterized 
previously by other authors [22-28], (Supporting Material Table S1). In all, 972 (76%) proteins 
were indicated as mitochondrial in earlier either MS-based or “in silico” studies (Supporting 
Material Fig. S1). We identified 34 mitochondrial proteins that are present in the MREF 
mitochondrial database [42] although, to our knowledge, they have not been identified previously 
by MS-based studies on the S. cerevisiae mitochondrial proteome[22-27], Prokish-unpublished 
dataset, [28] (Supporting Material Table S2). Our list of proteins contains representatives of 45 out 
of the 46 major functional modules of the yeast mitochondrial interactome constructed by Perocchi 
and co-workers [36] (Supporting Material Fig. S2 and Table S3).  
Similarly to other proteomic studies, the number of detected proteins was higher than the 
number of proteins in the accepted mitochondrial reference set. Two factors may explain this 
apparent inconsistency. First, it is possible that the mitochondrial reference set is not yet complete 
and that the detected proteins are new mitochondrial proteins, or second, our preparation procedure 
did not fully eliminate non-mitochondrial proteins. It has to be noted, however, that the main aim of 
our experiment was to identify differential proteins between [PSI
+
] and [psi
-
] strains. Therefore the 
possible presence of non-mitochondrial proteins does not compromise the validity of our results. 
In conclusion, our identification of mitochondrial proteins in [PSI
+
] and [psi
-
] strains, 
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proved to be of comparable quality to previous protein identification efforts. Thus we can state that 
the set of mitochondrial proteins considered in the differential analysis is reasonably complete and 
representative. 
3.2. Prohibitins and Cox2 among proteins identified by differential proteomics of the 
mitochondria of [PSI
+
] and [psi
-
] strains  
To obtain a list of proteins of which the levels are affected by the presence of prion [PSI
+
], two 
independent methods of differential proteomics, named FTICR and WPES, were used and each was 
repeated three times (see the Supporting Material and Method Section for details of the methods, 
the statistical analysis and hit acceptance criteria). Figure 1 shows the comparison of protein level 
as the [PSI
+
]/[psi
-
] ratios. Forty-one of these proteins showed the same direction of expression 
changes in both experiments (Supporting Material Table S4). This fairly large number of detected 
differential proteins indicates that the presence of prion [PSI
+
] in the yeast cytoplasm induces a 
complex response in mitochondria. 
 [PSI
+
]-dependent proteins identified in our experiment belong to several
 
annotation 
categories. [PSI
+
] mitochondria showed decreased levels of several subunits of respiratory 
complexes, such as Cox2, Atp1, Atp2, Atp3 and Sdh1. There were also decreased levels of some 
enzymes of isocitrate metabolism. In addition we observed marked changes
 
in the levels of some 
chaperones and receptors involved in mitochondrial protein import, such as Tom40, Tim13 and 
Ssc1. The identification of these proteins as affected by [PSI
+
] links the prion with the 
reorganization of the mitochondrial import apparatus. Interestingly, both prohibitins Phb1 and Phb2 
were also downregulated in the [PSI
+
] mitochondria. Phb1 and Phb2 prohibitins act as membrane-
bound chaperones involved in the stabilization of mitochondrial translation products including 
Cox2 [43-45]. Because of this relation, Cox2 and prohibitins are immediate neighbors in the yeast 
mitochondrial interactome [46] (Supporting Material Fig. S3). Moreover, Cox2 is known to be 
involved in prion-dependent phenomena in yeast [20]. Encouraged by the known functional links 
between Cox2, Phb1 and Phb2, we focused our attention on these three proteins.  
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Two independent proteomic methods showed that Cox2 and the two prohibitins, Phb1 and 
Phb2, are less abundant in mitochondria in [PSI
+
] cells. In the [PSI
+
] strain the Cox2 level was 
decreased over 3.5 fold (p=0.0048). The [PSI
+
]/[psi
-
] ratio for Cox2 was estimated on the basis of 
eleven peptides in FTICR and eight in the WPES experiment, respectively. Phb1 was decreased 1.9 
fold (p=0.058) as estimated on the basis of seven peptides in FTICR and ten in WPES. For Phb2 17 
peptides in FTICR, and 11 in WPES were used for ratio calculation giving a 1.3 fold decrease in 
[PSI
+
] cells (p=0.11). The signal amplitude values of Phb1, Phb2 and Cox2 peptides are presented 
in the Supporting Material, Fig. S4. 
3.3. Reduced levels of Cox2 and prohibitins in [PSI
+
] mitochondria detected by 
immunoblotting 
To provide independent confirmation of the MS differential analyses, mitochondria isolated 
from [psi
-
] and [PSI
+
] cells were analyzed by Western blotting with specific antibodies. The results 
(Fig. 2A) reproducibly confirm that the presence of [PSI
+
] reduces the levels of mitochondrial 
Cox2, Phb1 and Phb2.  We next investigated whether the amount of mitochondrial prohibitins was 
affected by curing of cells from [PSI
+
]. Yeast may be cured from the [PSI
+
] prion by overexpression 
or deletion of the gene encoding the Hsp104 chaperone [1, 2, 11]. We took advantage of two 
observations: first, that [PSI
+
] curing by Hsp104 stabilized Cox2 in the MB43-nam9-1 strain [20] 
and second, that prohibitins are known to stabilize mitochondrially synthesized proteins, including 
Cox2 [43-45]. Thus we considered the possibility that [PSI
+
] curing may increase the levels of 
prohibitins in mitochondria and that this effect is a prerequisite for Cox2 stabilization. Indeed, the 
Western blot analysis of the mitochondria (Fig. 2B) showed that deletion or overexpression of the 
HSP104 gene in [PSI
+
] MB43-nam9-1 cells resulted in an increase in Phb1 and Phb2 levels. These 
results clearly indicate a link between curing of the [PSI
+
] prion and the levels of prohibitins and 
Cox2 in mitochondria. 
For quantification, the intensities of bands were measured using nuclear-encoded mitochondrial 
malate dehydrogenase Mdh1 as an internal control. The results of MS and Western analyses 
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comparing the effect of [PSI
+
] were consistent, even in cells of different genetic background (Table 
1). Cox2 is a mitochondrially synthesized protein, the stability of which is known to be prion-
dependent [20], and our work confirmed this. In contrast, prohibitins are synthesized in the 
cytoplasm and then imported to mitochondria. The observed decrease in the amount of 
mitochondrial prohibitins might result from their lower synthesis in [PSI
+
] cells. Interestingly, 
Western blot analysis of total yeast extracts shows a decreased amount of Cox2 in the [PSI
+
] strain, 
but does not reveal differences between the levels of prohibitins in the [psi
-
] and [PSI
+
] strains (Fig. 
2C). This suggests that the observed depletion of mitochondrial prohibitins was due to their 
inefficient import into the mitochondria in cells with the [PSI
+
] prion.  
 3.4. [PSI
+
] causes enrichment of prohibitins in the cellular aggregates fraction  
[PSI
+
] is the prion conformation of the Sup35 protein, a cytoplasmic translation termination 
factor. [PSI
+
] affected the levels of mitochondrial prohibitins but not their total amount in the yeast 
cell (Fig. 2), suggesting a defect in intracellular distribution. This might be due to a physical 
interaction of prohibitins with Sup35 aggregates occurring in the cytoplasm and affecting their 
import to mitochondria.  
It has previously been shown that Sup35 forms high-molecular-weight aggregates in [PSI
+
] 
cells, co-sedimenting with the heavy polyribosomal fraction and even larger structures [47]. Thus 
distribution of prohibitins between the soluble and aggregated fractions could be influenced by the 
[PSI] status of the cells. To check this, extracts of isogenic [psi
-
] and [PSI
+
] strains were prepared 
using the clarifying spin to eliminate the remaining mitochondria (see Materials and Methods). 
Extracts were fractionated by centrifugation through a sucrose cushion, and the fractions were 
analyzed by immunoblotting using antibodies against Sup35, Phb1 and Phb2. In agreement with 
previous results [47], after centrifugation most of the Sup35 protein was found in the pellet fraction 
in the [PSI
+
] strain, whereas in the [psi
-
] strain Sup35 remained in the supernatant (Fig. 3, upper 
panel). Prohibitins were detected almost exclusively in the pellet fraction, although some remained 
in the sucrose cushion. The presence of prohibitins in the pellet cannot be attributed to the residual 
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presence of contaminating mitochondria, as their absence was carefully controlled by the absence of 
the other mitochondrial protein, aconitase (Aco1) in the pellet. Interestingly, both Phb1 and Phb2 
were relatively more abundant in the pellet fraction from the [PSI
+
] strain than in the respective 
fraction from the [psi
-
] strain (Fig. 3, lower panel). This suggests that prohibitins are partially 
trapped by cytoplasmic [PSI
+
] prion aggregates, which in turn should decrease their availability for 
import into the mitochondria.  
3.5. [PSI
+
] causes premature fragmentation of mitochondria  
 The yeast mutants with inactive prohibitin showed abnormal mitochondrial morphology and 
defects of mitochondria segregation, especially in old cells [48]. A recent study in mammals 
revealed that prohibitins determine cristae morphogenesis and formation of tubular mitochondrial 
ultrastructures, since 90% of PHB2-deficient mouse cells contained fragmented mitochondria [49]. 
We explored the possibility that [PSI
+
] could indirectly affect fusion of mitochondria in yeast by 
reduction of the levels of mitochondrial prohibitins. To investigate mitochondrial ultrastructure, 
[psi
-
] and [PSI
+
] cells were transformed with pYX323-mtGFP plasmid (2 μ, TRP1) encoding green 
fluorescent protein (GFP) containing a mitochondrial localization signal. To prevent the loss of 
plasmid, cells were cultivated in minimal medium lacking tryptophan. The growth rate was 
controlled by OD measurements, indicating no difference between [psi
-
] and [PSI
+
] strains. Cells 
were harvested at the same point in the late logarithmic phase and examined by confocal 
microscopy. Strikingly, [PSI
+
] cells contained 95% of fragmented mitochondria whereas the 
majority of [psi
-
] cells in the same phase contained regular tubular mitochondrial ultrastructures 
(Fig. 4). This showed premature fragmentation of mitochondria in [PSI
+
] cells, providing a link 
between the presence of cytoplasmic prion [PSI
+
] and defects in mitochondrial fusion, which may 
be caused by reduced prohibitins (see Discussion).  
 
 
 
 
4. Discussion 
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Several years ago it was reported that stability of the mitochondria-encoded respiratory 
chain subunit Cox2 in a mitochondrial ribosomal mutant nam9-1 depends on the yeast prion [PSI
+
] 
[20]. This observation is striking because the prion is located in the cytosol, whereas the synthesis 
and assembly of Cox2 takes place in mitochondria. In order to obtain a better insight into this 
unexpected relation, we used a proteomics approach to search for differences in the levels of 
mitochondrial proteins in prion-positive [PSI
+
] and prion-negative [psi
-
] cells. We obtained a list of 
44 mitochondrial proteins showing altered abundance depending on the presence of [PSI
+
]. Among 
those were Cox2 and several other subunits of cytochrome oxidase and mitochondrial ATPase. 
Importantly, the levels of the two prohibitins, Phb1 and Phb2, were also reduced in mitochondria of 
[PSI
+
] cells.  
Prohibitins are evolutionarily conserved eukaryotic proteins that assemble in a large ring 
complex bound to inner mitochondrial membrane [51-53].. Earlier findings in yeast identified 
prohibitins in assemblies with ATP-dependent protease m-AAA involved in chaperoning and 
turnover of mitochondrial inner membrane proteins [43, 44]. Yeast mutants lacking functional 
prohibitins show accelerated proteolysis by m-AAA protease suggesting a regulatory role of 
prohibitins in the quality control of proteins in inner membrane [45, 50]. Phb1/2 complex, 
reminiscent of Hsp60-like chaperones, is proposed to act as a novel type of membrane-associated 
chaperone/holdase involved in higher order organization of respiratory chain complexes [51-53]. 
Using molecular methods provide evidence that Phb1, Phb2 and Cox2 are less abundant in 
mitochondria in [PSI
+
] cells, thus confirming proteomic results and suggesting lowered 
mitochondrial prohibitins as a potential reason of Cox2 destabilization.  
Another function of prohibitins described recently in mammals is the processing of the 
dynamin-like GTPase OPA1, an essential component of the mitochondrial fusion machinery [49]. 
OPA1 is a homologue of yeast Mgm1 protein also involved in mitochondria fusion [54]. Both OPA1 
and Mgm1 exist in forms of different lengths and their function is regulated by proteolytic cleavage 
[55, 56] Only a long form of OPA1 (L-OPA1) is fusion competent [55], and maintenance of this 
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form requires prohibitins [49]. Depletion of prohibitins induces L-OPA1-dependent fragmentation 
of mitochondria and apoptosis. The mechanism underlying the selective loss of L-OPA1 in the 
absence of prohibitins remains to be elucidated [57].  
Here we detected [PSI
+
]-dependent premature fragmentation of yeast mitochondria in post-
exponential growth phase. It is currently unknown whether the low level of mitochondrial prohibitins 
in [PSI
+
] cells can provide the rationale for the observed negative effect on mitochondrial fusion. 
One interesting hypothesis is that depletion of prohibitins could contribute to the defect in the 
function of Mgm1, the OPA1 homologue, in the fusion of yeast mitochondria. Although Mgm1 
processing is not strictly required for mitochondrial fusion [58], the balanced formation or regulated 
inter-conversion of the two isoforms of Mgm1 appear crucial [59]. Characterization of the effect of 
prohibitins on Mgm1 requires further study. Among the other mitochondrial proteins found to be 
affected by [PSI
+
] in this work, the presence of Hsp78 is remarkable, because this chaperone 
functions in restoration of the mitochondrial network following heat stress [60].  
Although the overall level of expression of prohibitins is the same in the [PSI
+
] and [psi
-
] 
strains, the PSI status affects their distribution within the cell. We were interested in why the 
mitochondrial localization of prohibitins was reduced by the [PSI
+
] prion state. Fractionation of 
mitochondria-free lysates for soluble and aggregate parts showed enrichment of prohibitins in the 
aggregate fraction in [PSI
+
] cells. This result suggests some interaction of Phb1/Phb2 with [PSI
+
] 
possibly leading to sequestration of prohibitins by prion aggregates. The effect of [PSI
+
] on 
sequestering of another cytoplasmic protein, translation termination factor Sup45, has been studied 
in the past, but the results were controversial. Sup45 was reported to be present in [PSI
+
] aggregates 
in some [21, 61] but not other studies [62] and a decisive model of Sup45 sequestering is lacking. 
Similarly, further experiments are required to demonstrate and characterize a specific interaction of 
prohibitins with [PSI
+
] aggregates. Here we just propose that the newly synthesized prohibitins are 
titrated by [PSI
+
] aggregates in the cytosol before they reach mitochondrial location and therefore 
their level in mitochondria is lowered, which in turn reduces the stability of Cox2. Moreover, we 
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believe that prohibitins are not the only component mediating the effect of the [PSI
+
] prion on 
mitochondrial function and the roles of other mitochondrial proteins identified by our proteomic 
study is worth to study as well.  
A different scenario may be proposed of how presence of [PSI
+
] aggregates interferes with 
mitochondrial function. Inefficient termination in cells containing [PSI
+
] potentially allows for 
readthrough of stop codons nuclear mRNAs. Leakiness of stop codons is considered to be the 
reason for a variety a weak phenotypes manifested by [PSI
+
] strains [10]. Nuclear-encoded 
mitochondrial proteins might be expressed in a C-terminally extended version(s) when low levels of 
functional Sup35 allow readthrough of nonsense codons. However, in this and other published 
studies no experimental evidence of C-terminally extended proteins in [PSI
+
] mitochondria has 
been found.  
The overall data presented here support the model that in S. cerevisiae the prion [PSI
+
] 
interacts with prohibitins and possibly other proteins in the cytosol and thereby alters their 
distribution to mitochondria. Thus the hidden phenotypic variation generated by [PSI
+
] may result 
from subtle alteration in sorting of particular proteins between cellular compartments. It is possible 
that some of the [PSI
+
] manifestations can be related to the ability of Sup35 prion aggregates to 
titrate host proteins with important functions though this suggestion has never been supported. 
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Figure Legends 
Fig. 1 . Proteins showing [PSI
+
]-dependent abundance in yeast mitochondria. The [PSI
+
]/[psi
-
] 
ratios of differential proteins (log scale) detected by the two independent differential proteomic 
methods: FTICR and WPES (see text). The ratio obtained for each protein with the FTICR method 
is shown as a red bar and with WPES as a black bar, and the corresponding protein name 
abbreviation is marked along the upper horizontal axis. For the majority of proteins (41 out of 44) 
both methods gave the same direction of change i.e. up- or downregulation, however, the degree of 
change was often substantially different. Note the Phb1, Phb2 and Cox2 proteins (marked in green) 
downregulated in [PSI
+
], as described in detail in the text. 
Fig. 2.  
[PSI
+
] decreases amounts of Phb1, Phb2 and Cox2 in mitochondria.  
Western blot analysis of Cox2, Phb1 and Phb2 levels in mitochondrial (A, B) and total protein 
extracts (C) prepared by alkaline lysis. Proteins were isolated from isogenic [psi
-
] and [PSI
+
] strains 
GT197 and GT81-1D (A, C) or isogenic derivatives of MB43-nam9-1 strain cured from [PSI
+
] by 
deletion [] or overexpression [↑] of the HSP104 gene (B). The levels of Hsp104 were determined 
in the total extracts. Mitochondrial malate dehydrogenase (Mdh1) was used as a loading control.  
.  
Fig. 3. Abundance of prohibitins in cellular aggregates depends on the [PSI] state of the cell. 
 Lysates of [psi
-
] and [PSI
+
] strains (GT197 and GT81-1D) were prepared as described in the 
Materials and Methods and were fractionated by centrifugation through a sucrose cushion. The 
distribution of Phb1, Phb2 and Sup35 between the supernatant soluble fraction, sucrose layer and 
high molecular structures in the pellet was determined by immunoblotting. To confirm that other 
mitochondrial proteins are not present in the pellet, the blot was also decorated with an antibody 
specific for aconitase Aco1, the protein imported to mitochondria from the cytoplasm. The gel was 
loaded using 20 μg of protein per lane for the supernatant and sucrose fractions and 5 μg of protein 
per lane for the pellet fraction.  
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Fig. 4. Fragmentation of mitochondria in prohibitin-deficient [PSI
+
] cells.  
[psi
-
] and [PSI
+
] strains (GT197 and GT81-1D) were transformed with pYX323-mtGFP plasmid 
encoding green fluorescence protein (GFP) with a mitochondrial localization sequence and 
analyzed by confocal laser scanning microscopy. Reconstruction of the mitochondrial network was 
done from about ten confocal sections with intervals of 0.5 m and 1024 x 1024 resolution. The 
images presented are representative for [psi
-
] and [PSI
+
] cells. More than 400 cells were scored per 
experiment. The percentage of cells with tubular mitochondria is indicated.  
 
 
 
Table Legends 
Table 1  
 Levels of Phb1, Phb2 and Cox2 in [PSI
+
] versus [psi
-
] mitochondria. 
[PSI
+
]/[psi
-
] protein ratios were measured by densitometry of Western blots and by differential 
proteomics. 
In order to determine the relative amount of proteins in [PSI
+
] and [psi
-
] strains by immunoblotting, 
the amount of each protein present in [PSI
+
], corrected by the loading control, was set to 1. Column 
1 represents the quantified results of immunoblotting analysis of Phb1, Phb2 and Cox2 in 
mitochondria from [PSI
+
] and [psi
-
] strains GT197 and GT81-1D (Fig. 2A). Columns 2 and 3 show 
the quantified results of the immunoblotting analysis of Phb1 and Phb2 in mitochondria from 
different pairs of isogenic [PSI
+
] and [psi
-
] strains in the genetic background of MB43-nam9-1:: 
[PSI
+
] and its [psi
-
] derivative derived by deletion (column 2) or overexpression (clolumn 3)  of the 
gene encoding Hsp104 chaperone (Fig. 2C). The complex effect of Hsp104 on Cox2 levels in 
[PSI
+
] cells was determined previously [20] 
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[PSI
+
]/[psi
-
] protein ratios for Phb1, Phb2 and Cox2 were determined independently by using two 
MS-based methods, FTICR and WPES, as described in the text and presented in the Supporting 
Material (Table S4, Fig. S4). Of note is the consistency between the numbers obtained by each 
method. 
Table 1. 
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Abbreviations 
FC – Fold Change, equal to the ratio of protein levels for upregulated proteins (ratio>1) and to 
the reciprocal of the ratio for downregulated proteins (ratio<1).
FDR - False Discovery Rate
FTICR - Fourier Transform Ion Cyclotron Resonance
IEF - IsoElectric Focusing
IPG-immobilized pH gradient
LC-MS – Liquid Chromatography coupled to Mass Spectrometry in survey scan mode
LC-MS-MS/MS – Liquid Chromatography coupled to Mass Spectrometry in data-dependent 
switch to fragmentation mode
LTQ – Linear Trap Quadruple
MREF – Mitochondrial REference Dataset (according to [42])
MS – Mass Spectrometry 
MS/MS – Mass Spectrometry in peptide fragmentation mode
OD – Optical Density
WPES – Waters Protein Expression System
Protein identification step
The identification of mitochondrial proteins derived from [PSI+] and [psi-] strains was carried 
out by several rounds of LC-MS-MS/MS experiments using an LTQ FTICR spectrometer. 
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The analysis was carried out in two stages. In the first stage, referred to as “LC-MS-MS/MS”,
LC was the only fractionation step preceding the MS analysis of the tryptic digest of total 
mitochondrial proteins. Data obtained were then compared to a protein sequence database 
with the MASCOT [63] search engine. In stage two the sample was further fractionated by 
isoelectrofocusing and each fraction was subjected separately to LC-MS-MS/MS analysis 
(referred to as IEF-LC-MS-MS/MS). Additional MASCOT runs using the datasets from both 
stages were carried out against randomized databases, for calculation of the false discovery 
rate (FDR) values of our database’s search procedures. These additional runs showed that the 
FDR = 0.3%, i.e. accepting one false positive for each 300 true positive protein hits, 
corresponding to a MASCOT score of 40. Based on this result the protein hit was accepted if 
the list of assigned peptides contained at least one peptide with a score larger than 40. 
In the first stage a list of 865 proteins was obtained. From this list, 160 protein identifications 
were based on two peptides and 358 on one peptide, so for 60% of protein hits the peptide 
coverage was insufficient. In the second stage (IEF-LC-MS-MS/MS), to obtain an increased 
coverage of mitochondrial proteins, the data collected from multiple LC-MS-MS/MS 
experiments were merged into one input data file, containing 56088 MS/MS fragmentation 
queries, and subjected to MASCOT database search and FDR analysis. This experiment 
resulted in an expanded list of 1064 proteins identified in stage two. This list was compared 
with the list of 865 proteins obtained in stage one. Stage two analysis confirmed the 
identification of 654 (76%) proteins from stage one. This means that a quarter of proteins 
from stage one were not confirmed in stage two. Interestingly, eight proteins identified with 
>=5 peptides in stage one did not appear in the list in stage two. This indicates the 
insufficiency of the narrow pH range (3.5–4.5) of the IEF gel used here, which might be the 
reason for loss of peptides originating from basic proteins and lack of detection of some 
proteins in the expanded experiment. On the other hand, in stage two we detected >400 
proteins that were not detected in stage one. Twenty-nine proteins identified with five or more 
peptides in the second stage did not appear in the list in stage one. For example, the Hpd1 
protein identified in the second stage by 47 peptides (Mascot Score = 3974) was not detected 
in the first stage. The complementarity of different proteomic approaches has frequently been 
noted (see e.g. [27]). Of the 358 proteins identified in the stage one analysis by a single 
peptide hit, 199 were confirmed. In the case of double-peptide identifications – 130 of 160 
proteins were confirmed using the peptide IEF-LC-MS-MS/MS approach. In total 189 of 
these protein hits were not confirmed in the stage two analysis and were not included in the 
differential analysis. The final protein list assembled from both stages consisted of 1275 
proteins (Table S1). The protein list obtained in this study was compared with the 
mitochondrial proteome characterized previously by other authors [22-28]. 753 proteins (59% 
of 1275) were found previously by MS-based mitochondrial proteome identification 
approaches [22-28]. Our dataset was also evaluated against “in silico” predictions of 
localization provided by the PSORT [64], Predator [65] and SubLoc [66] databases. 
Mitochondrial localization was predicted for 756 proteins (59% of 1275). In all, 972 (76%) of 
the 1275 proteins were indicated as mitochondrial in previous either MS-based or “in silico” 
studies. A Venn diagram comparing the results of our protein identification analysis with other 
methods characterizing the mitochondrial proteome is presented in Fig. S1. The level of 
agreement of our protein list with the MREF, the mitochondrial protein reference set in the 
Mitop2 database [42] that contains experimentally validated mitochondrial proteins, is also an 
important indicator of the quality of the present work. We detected 437 (80%) of the 546 
proteins present in the MREF [42]. Thirty-four of these 437 proteins (listed in Table S2) were, 
to the best of our knowledge, identified in an MS-based study of yeast mitochondria for the 
first time. For comparison the fractional coverage of the MREF obtained in other studies [22, 
25, 23, 27] was as follows: 145 (26%), 393 (72%), 158 (29%) and 435 (80%), respectively. 
Our list contains representatives of 45 out of the 46 major functional modules of the 
yeast mitochondrial interactome constructed by Perocchi and co-workers [36]. Among the 164 
predicted functional modules, 46 with five or more protein partners were considered as major. 
The coverage of protein identification obtained here within the individual 46 mitochondrial 
modules is presented in Fig. S2. For example all 13 proteins from the TCA cycle and 10 of 14 
proteins from respiratory complex chain IV were detected. Within 34 of the 46 modules we 
were able to detect over 60% of partner proteins. Detailed information concerning 
identification of the components of the mitochondrial functional modules in this and other 
studies is presented in Table S3.
Differential proteomics 
Following the protein identification step, two independent LC-MS differential methods 
(named FTICR and WPES) were used to obtain a list of proteins, the levels of which are 
affected by the presence of prion [PSI+] (Table S4). Details of the methods, the statistical 
analysis and hit acceptance criteria are described below. 
A. FTICR system 
A.1. Sample preparation
Prior to MS analysis, crude mitochondria were resuspended in 50 mM ammonium 
bicarbonate/0.2% RapiGestTM SF solution (Waters), which allows for complete lysis of 
mitochondria as indicated by the clarity of the resulting resuspension. Trypsin (sequencing 
grade; Promega, Madison, WI) was added at the concentration of 20 ng/μl and proteins were 
digested overnight at 37 °C. The enzyme to substrate ratio was 1:100 (w/w). The resulting 
peptide mixture was reduced with 10 mM DTT (Roth) and alkylated using 50 mM IAA. 
Samples were diluted with 0.1% TFA to the concentration of 0.1 µg/µl. 2 µg of tryptic 
peptides in 20 µl were loaded on the column in each injection.
A.2. Liquid chromatography
Liquid chromatography (LC) – mass spectrometry (MS) analyses of the tryptic mixture of 
mitochondrial peptides were carried out using a nano-Acquity (Waters) LC system coupled to 
a LTQ FTICR (Thermo) mass spectrometer. Spectrometer parameters were as follows: 
capillary voltage: 2.5 kV, cone: 40 V, N2 gas flow: 0, range 300–2000 (m/z). The spectrometer 
was calibrated on a weekly basis with Calmix (caffeine, MRFA, Ultramark 1621). The sample 
was first loaded from the autosampler tray cooled down to 10 oC to the pre-column 
(Symmetry C18, 180 µm × 20 mm, 5 µm (Waters, 186003514)), using a mobile phase of 
MilliQ H2O acidified by 0.1% FA. The peptides were then transferred to the nano-UPLC 
column (BEH130 C18, 75 µm × 250 mm, 1.7 µm (Waters, 186003545)) by a gradient of 5–
30% acetonitrile, 0.1% FA in 160 min and directly eluted to the ion-source of the mass 
spectrometer. [psi-] LC runs were separated from [PSI+] LC runs by a blank run, ensuring 
lack of carry-over of the material from the previous runs.
A.3. Mass spectrometry
The qualitative (LC-MS-MS/MS peptide identification runs) and quantitative (profile type 
peptide peak amplitude LC-MS runs) datasets were collected in separate experiments.
A.3.1. Qualitative runs. For peptide identification, a series of four LC-MS-MS/MS runs on 
[psi-] and [PSI+] samples were carried out with the spectrometer running in the data-
dependent switch to peptide fragmentation mode (MS/MS). Up to ten fragmentation 
processes were allowed for each MS scan. Each run covered one of four sectors of m/z 
values: 300–600, 500–800, 700–1000, 900–2000. The sector overlap was introduced to avoid 
loss of instrument sensitivity at the high m/z value sector border. As a result, four sequencing 
runs were collected for each [psi-] and [PSI+] sample. This approach has been found to 
significantly improve the coverage of peptide identification.
The lists of parent masses and daughter fragment masses from both [psi-] and [PSI+] samples 
were prepared (merged into a single file) for the database search with MascotDistiller 
v2.1.1.0 software (MatrixScience) and searched against the Saccharomyces cerevisiae protein 
database from
ftp://genomeftp.stanford.edu/pub/yeast/sequence/genomic_sequence/orf_protein/orf_trans_all
.fasta.gz containing the amino acid sequences of all systematically named ORFs with the 
Mascot (Matrixscience) v2.3 search engine (8-processor site license). The protein database 
was enriched with trypsin and common contaminant keratin sequences. Mascot search 
parameters were as follows: fixed modification: Cys carbamidomethylation; variable 
modification: Met oxidation, Asn Gln deamidation; peptide mass tolerance: 40 ppm; fragment 
mass tolerance: 0.8 Da; enzyme: semi-trypsin. In total 42316 peptide fragmentation spectra 
were included in the search. The list of peptides from all eight [psi-] and [PSI+] runs matching 
the acceptance criteria (Mascot peptide score above 40) was merged into one peptide 
sequence list (Selected Peptides List – SPL) using an in-house MScan program 
(www.ire.pw.edu.pl/~trubel/soft/ms/mascotscan/). This list contains 6390 peptides, 
corresponding to 865 proteins along with the peptide m/z and LC retention time values. SPL 
was used further to overlay the results of qualitative and quantitative runs by tagging the 
corresponding MS peptide signals in quantitative, profile type data sets with peptide sequence 
tags, based on peptide m/z and retention time values, using in-house software (Poznański J. et 
al., unpublished) (see below).
In addition, to confirm the statistical validity of accepted protein hits the false-positive rate 
(FDR) values were calculated by performing Mascot searches on a decoy database, merged 
from an ordinary protein database and it's randomized version created using a Perl script 
supplied by Matrix Science (http://www.matrixscience.com/help/decoy_help.html). 
Computation was performed using a module of the in-house developed software MScan. 
Briefly, the estimated FDR value is defined as double the number of queries assigned by 
Mascot to randomized sequences divided by the number of queries assigned to sequences 
originating from non-decoy yeast proteins. Both randomized and non-randomized hits must 
achieve a peptide score exceeding a given threshold, which can be manipulated depending on 
which FDR is adequate. For our experiment the accepted Mascot peptide score threshold of 
40 corresponds to 0.29% of false positive identifications.
A.3.2. Quantitative runs. Profile (quantitative) runs were carried out in triplicate, as separate 
LC-MS runs for both [psi-] and [PSI+] using the same acetonitrile gradient. The spectrometer 
resolution was set at 50000. Raw datasets of collected mass spectra were converted to 
NMRPipe software: http://spin.niddk.nih.gov/NMRPipe/ data format by an in-house 
MS2Pipe data conversion tool. At this stage a series of MS spectra becomes a 2D array (2D 
peptide heat map) in which every feature represents the signal amplitude (quantity of ions) at 
a given m/z, eluted at a given time. The NMRPipe program was designed and thoroughly 
tested by many research groups for the analysis of nuclear magnetic resonance protein 
spectra. However, it can also be used for the analysis of multidimensional datasets of any 
kind, including LC-MS data, which have an inherent 2D character. NMRPipe along with 
Sparky NMR assignment software [67](converted to accept mass spectrometry data into an 
in-house “MSparky” tool (www.ire.pw.edu.pl/~trubel/soft/ms/msparky/)) allow for efficient 
multidimensional data processing and visualization. The data analysis steps may include 
noise reduction, smoothing, peak picking, conversion of a set of mass spectra to a list of mass 
peaks along with their amplitudes and coordinates on the m/z and retention time axis. Also 
when supported by an in-house procedure (TagProfile) it allows for identification of MS 
peaks corresponding to given peptides from the list, based on their m/z values and retention 
time coordinates providing an overlay of qualitative peptide sequence results on quantitative 
MS profile data. 
A.3.3. Overlay of qualitative peptide sequence list on quantitative profile datasets. In the 
next step of analysis the peptides from SPL obtained from qualitative runs were overlaid on 
peptide heat maps using in-house TagProfile software (Poznański, J. unpublished) so that a 
monoisotopic peak on the profile map is assigned to each peptide from the list of identified 
peptides, if found. The program allows for efficient correction of the unavoidable differences 
in retention times between runs. The actual, measured retention time is recalculated as 
relative retention time domain to best overlay the qualitative run retention times of the 
peptides and the retention times of their corresponding peaks. The details of the program will 
be described elsewhere. As a result, selected monoisotopic peaks on the map become tagged 
with a peptide identity tag (Fig. S5). A peak integration tool is later used to carry out the 
integration of peaks (2, 3 or more) from tagged isotopic envelopes and the peptide list is 
expanded by fitted peak height and peak volume. On this list peptides that were not found or 
were found but did not meet the acceptance criteria are highlighted and can be verified or 
corrected manually in an interactive fashion using an in-house MSparky tool. Acceptance 
criteria include m/z value deviation, retention time deviation, Fit Root Mean Squared Error, 
Envelope Root Mean Squared Error (i.e. the deviation between the expected isotopic 
envelope peak heights and their experimental values) and charge state value. Peak volumes or 
amplitudes of corresponding peptides in two samples can be compared in the form of a scatter 
plot as described in Fig. S6.
A.3.4. Relative quantitation. The amplitude of the isotopic envelope corresponding to the 
various charge state signals of the peptide is used as a measure of relative peptide abundance. 
For the peptides of interest their corresponding monoisotopic peaks on the heat maps are 
localized using the ProfileTag tool, and their sequence tags are added to the heat map as 
shown in Fig. S5. Peaks from all tagged isotopic envelopes are then integrated by 2D fitting 
of a Gaussian curve to the peak by the least squares method. The peak amplitude is defined as 
the height of the peak at its maximum calculated from the best fit of a Gaussian curve (“peak 
fit height” option in MSparky). Peptide relative abundance is calculated as the sum of peak 
amplitudes of two peaks from its isotopic envelope (monoisotopic peak and one peak 
corresponding to the presence of one 13C atom). The list of peaks containing peptide 
sequences, charge, m/z, rt, and fit height was exported to file and analyzed using Perl scripts 
designed for statistical computing. A resampling procedure [68-70] with FDR [71, 72] control 
was used for estimation of significance. In the FTICR-based differential approach the 
estimated ratio was regarded as statistically significant if p<0.1, and 100 proteins with the 
lowest p values were selected for further analysis. 
B. Waters Protein Expression System (WPES)
B.1. Sample preparation 
Crude mitochondria were solubilized essentially in the same way as in the FTICR-based 
differential system except for the use of a 0.1% RapiGestTM SF solution. Proteins were 
reduced (10 mM DTT) and alkylated (10 mM IAA) prior to enzymatic digestion overnight 
with trypsin 1:50 (w/w) enzyme: protein ratio at 37 °C. RapiGest was removed by addition of 
2 µl concentrated HCl, followed by centrifugation, and then the supernatant was collected. 
Samples were diluted with 0.1% formic acid to an appropriate final working concentration 
prior to analysis – corresponding to 0.3 µg protein digest loaded on the column.
B.2. LC conditions
Two experiments with different LC conditions were performed using WPES. Quantification 
experiments were conducted using a 180 min gradient at 250 nl/min (5 to 40% acetonitrile 
over 180 minutes) or 90 minutes (5 to 40% acetonitrile over 90 minutes) on a nanoACQUITY 
UPLC®System equipped with a Symmetry C18 pre-column (180 µm × 20 mm, 5 µm (Waters, 
186003514)) and utilizing a 1.7 µm BEH C18 NanoEaseTM 75 µm x 20 cm column. Each 
sample was analyzed in triplicate in each LC condition. 
B.3. MS conditions
The Q-Tof PremierTM mass spectrometer was set to shift between normal (5 eV) and elevated 
(25–40 eV) collision energies on the gas cell, using a scan time of 1.5 s per function over 50–
1990 m/z. All remaining settings were set according to the WPES manufacturer’s 
recommendations.
B.4. Data processing and protein identification
Data alignment, protein identifications and quantitative analysis were conducted using 
dedicated algorithms (Waters Protein Expression Informatics-PLGS v2.3 build 020) and 
searching the S. cerevisiae protein database from www.yeastgenome.org enriched with trypsin 
and common keratin sequences as described for LTQ FTICR analysis. The principles of the 
applied data clustering and normalization have been explained in great detail in previous 
publications [73, 74]. In WPES the estimated ratio was regarded as statistically significant if 
the probability of regulation(p) ranged from 0 to 0.1, and 100 proteins with the lowest p 
values for the obtained [PSI+]/[psi-] ratios were accepted for further analysis 
Forty-four proteins were indicated as differential by FTICR and WPES. In general, the 
qualitative agreement between the two methods was good. Out of 44 proteins identified by 
both methods as differentially expressed, 41 showed the same direction of expression changes 
in both experiments (Table S4). To assess the agreement on a quantitative level, the 
[PSI+]/[psi-] ratio values from both differential systems were compared for the 44 proteins 
common to both systems (Fig. 1). Only 57% of proteins had FC (fold change) values that did 
not differ by more than 30%. This observation indicates that the results of MS-based 
differential proteomic experiments have to be treated with caution especially with regards 
their quantitative aspects, and that an independent confirmatory test is still a must.
Supporting Material Section S2 - Legends for Supporting Tables and Figures
Supporting Material Table S1 List of all 1275 proteins identified in this study using the LC-
MS-MS/MS method (both IEF and non-IEF approach). Columns from left to right contain: 1. 
Module number according to [36]; 2. Module name if provided [36]; 3. SGD protein name 
and ORF name in parentheses; [PSI+] 4.-7. Mascot MudPit score and number of peptides 
identified from each protein in two steps of the analysis ("LC-MS-MS/MS only" and "peptide 
IEF-LC-MS-MS/MS"); 8.-14. Presence in previous MS-based studies [22-27, Prokish-
unpublished dataset] marked by ”x”, 15.-17. ”In silico” prediction of mitochondrial 
localization according to PSORT [64], Predotar [65] (where ** stands for “mitochondrial”, 
and * for “possible mitochondrial”), SubLoc [66]; 18. Presence in the MREF (release 2007) 
[42]. 
Supporting Material Table S2. List of 34 proteins identified in mitochondrial preparations in 
this work that are present in the MREF database [42] and which, to our knowledge, have not 
been identified previously by MS-based studies on the S. cerevisiae mitochondrial proteome 
[22-28, Prokish-unpublished dataset]. 
Supporting Material Table S3. List of predicted mitochondrial functional modules [36] with 
number of proteins expected for each module (column 3) and number of proteins detected in 
this (column 4) and other work [22-27, Prokish-unpublished dataset] (columns 5-11). 
Supporting Material Table S4 List of all proteins (156) for which the [PSI+]/[psi-] ratios 
were measured with highest confidence. One hundred proteins from each differential system 
(FTICR or WPES) with the lowest estimated p values were accepted. In columns 1, 2, 3, the 
module number, module name (if present), as introduced in [36], and protein ORF name, are 
given, respectively. The protein [PSI+]/[psi-] ratio values and p-values are shown in columns 
4 and 5 (FTICR method) and 6 and 7 (WPES method). Ratio values are the mean of three 
independent experiments. Forty-one proteins for which the direction of change was the same 
in both methods are marked in green. Eight proteins which showed changes in opposite 
directions are marked in red. The mean FC value is given in the last column. p value 0.00 
means p<0.01.
Figure S1. Venn diagram illustrating the overlap of yeast mitochondrial protein lists 
obtained in this and earlier work. Proteins attributed to yeast mitochondria (2537 proteins 
in total) are grouped in three datasets: proteins identified in this study (1275 proteins), 
proteins found previously in MS-based identification of mitochondrial proteins [22-28] (1148 
proteins), and proteins implicated as mitochondrial by “in silico” predictions of mitochondrial 
localization (PSORT [64], Predator [65], SubLoc [66] – 1770 proteins). The total number of 
entries for each dataset along with the fraction (in %) of the total protein number is indicated 
outside each circle. The number inside each circle indicates the number of common entries 
between the datasets. Proportions of circles and overlapping regions reflect the fractional 
value of each category. A total of 537 proteins are common to all three groups, and 972 
(537+216+219) proteins found in this study have already been attributed to mitochondria in 
previous work. A total of 753 proteins (537+216 – 59% of 1275) were found previously by 
MS-based mitochondrial proteome identification approaches. Mitochondrial localization was 
predicted for 756 proteins (537+219 – 59% of 1275). A total of 303 proteins were identified in 
yeast mitochondrial preparations for the first time.
Figure S2. Proteins subjected to differential proteomics cover major yeast mitochondrial 
functional modules. The GO terms-based module map of 46 functional modules consisting 
of five or more proteins is shown according to [36], with the indicated fraction of proteins 
identified in this work by two-step LC-MS-MS/MS analysis. Proteins identified at both stages 
of the analysis (LC-MS-MS/MS without or with peptide IEF prefractionation) are marked in 
red. Proteins identified exclusively in the first stage – LC-MS-MS/MS – are marked in green. 
Proteins identified only in the second stage of the analysis – IEF-LC-MS-MS/MS  – are 
marked in blue. Grey dots indicate proteins not detected in this study. Modules were named 
and assigned to cellular compartments based on GO terms. The localization of modules in 
three different compartments – nucleus, mitochondria, and cytoplasm – is indicated by sectors 
of different colors. When a module contains a mixture of proteins with different localizations 
it is annotated as shared between the different compartments. Modules that are shared 
between mitochondria and the nucleus or mitochondria and the cytoplasm belong to the green 
and yellow sectors, respectively. Cytoplasm refers to all contents of the cell excluding the 
mitochondria and nucleus but including the plasma membrane and other sub-cellular 
structures. For the majority of modules the coverage exceeds 50% and only in one module 
was no protein detected (Mismatch repair).
Figure S3. Prion-dependent changes detected in this work in yeast mitochondrial 
proteome overlaid onto the mitochondrial interactome. A simplified interactome [46] is 
shown that is limited to proteins present in the MREF [42] and their direct neighbors. 
Upregulated proteins are marked as red squares and downregulated proteins as blue squares 
with the color intensity depending on the log (fold change) values as described in the color 
scale shown. The enlarged part of the interactome shows a direct link between Cox2 and 
prohibitins.
Figure S4. MS analysis of Phb1, Phb2 and Cox2 peptide levels in [psi-] and [PSI+] 
strains. Comparison of MS signal intensities in [psi-] (black bars) and [PSI+] (red bars)
obtained with the FTICR method (A), (C), (E), and WPES method (B), (D), (F) for individual 
peptides of Phb1 (A), (B), Phb2 (C), (D) and Cox2 (E), (F) proteins. The mean value of 
peptide signal amplitude (in arbitrary units) in three independent experiments is shown, with 
corresponding error bars. These results reveal a decrease in MS signals corresponding to 
prohibitins and Cox2 protein in the mitochondria of [PSI+] yeast.
Figure S5. 2D LC-MS map of tryptic peptides from the S. cerevisiae mitochondrial 
fraction of yeast. A heat map of peaks detected in a typical LC-MS analysis of digested 
mitochondrial fraction is presented in two panels of different magnification. Their retention 
times are shown on the vertical axis, m/z values on the horizontal axis, and the peak 
amplitudes are color-coded in a hypsometric rendering with their values increasing from red 
to blue. The map represents smoothed raw data with no further processing. Each peptide is 
represented by a characteristic group of peaks, an isotopic envelope, which originates from 
the presence of different isotopes, mainly 13C instead of 12C, in a fraction of the molecules. 
The upper panel shows a full range dataset with m/z values between 300 Th and 1500 Th and 
retention times between 40 and 180 min. Lower panel – a magnified section of 595–596 in the 
m/z and 96–108 min in the RT domain. The magnified panel shows that even peptides with 
close m/z and retention time values generate well-resolved isotopic envelopes. Monoisotopic 
peaks of isotopic envelopes assigned to peptides from the Selected Peptides List (refer to 
Supporting Material Section S1) are tagged by the protein name from the SGD, peptide 
sequence and charge. Crosses indicate two peaks of the isotopic envelope included in the 
quantification. 
Figure S6. Scatter plots of MS signal intensities of 6390 peptides from mitochondrial proteins 
of [psi-] and [PSI+] strains compared by a typical differential experiment (FTICR method). 
(A) Comparison of signal amplitudes on a log scale of two replicates of [psi-] sample. (B) The 
amplitude of the peptide signal in the [PSI+] sample is shown on a log scale on the vertical 
axis and the signal of the same peptide in the [psi-] sample is shown on the horizontal axis. 
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Cox9 (YDL067C) 110.7 3 87.4 2 X X X X X * X
Cox4 (YGL187C) 2580.9 19 2199.9 14 X X X X X X * * * X
Cox12 (YLR038C) 314 5 459.6 3 X X X X X X X
Cox6 (YHR051W) 1386.6 8 902.3 19 X X X X X X * * * X
Yhb1 (YGR234W) 58 1 120.3 3 X X X X X X
Cox13 (YGL191W) 101 2 75.5 6 X X X X X X * * * X
Cox8 (YLR395C) 41 1 X X X X * * * X
Cyc7 (YEL039C) 288.6 2 X X X * X
Cox5a (YNL052W) 1402.7 9 978.1 12 X X X X X X * * * X
Cox2 (Q0250) 984.3 9 588.7 8 X X X X X X
Cox1 (Q0045) 795.8 1 397.3 3 X X X X X
2 Ykr016w (YKR016W) 2641.5 25 2502 25 X X X X X * * 
Coq9 (YLR201C) 166 1 356.3 2 X X X X X * * * * X
Atp23 (YNR020C) 121 1 42.5 1 * * X
Top2 (YNL088W) 64 2 X X *
Lst8 (YNL006W) 88.5 1
Avo2 (YMR068W) 44 1
Odc2 (YOR222W) 63 2 X X X X * X
Yjr085c (YJR085C) 70 1 X X X * 
Mmm1 (YLL006W) 46 1 43 1 X X X X
Phb2 (YGR231C) 851.5 12 773 8 X X X X X * * X
Phb1 (YGR132C) 459.8 11 1039 15 X X X X X X X
Mdm32 (YOR147W) 91.8 3 162.3 3 * X
Mpm1 (YJL066C) 958.1 6 2408.6 20 X X X X X
Mdm10 (YAL010C) 46 1 173.3 3 X X
Mdm34 (YGL219C) 97 1 180.5 2 X X X
1
Respiratory Chain 
Complex-IV
3
6
Mitochondrial 
organisation and 
morphology
4 Cell growth regulation
5
Other MS based proteomic 
studies
"in silico" 
prediction of 
mitochondrial 
localization
M
R
E
F
 [42] (release 2007)
Modules according to Perocchi at 
al. [36]
LC-MS-MS/MS only
peptide IEF-LC-MS-
MS/MS
Supporting Table S1
Click here to download Supplementary Material (for online publication): Supporting TableS1.xls
Abc1 (YGL119W) 124.3 6 X X X X * * * * X
Coq3 (YOL096C) 145 3 228.8 3 X X * * X
Coq5 (YML110C) 628.8 2 1378.2 15 X X X X * * * X
Ypl109c (YPL109C) 177.1 4 X X
Coq6 (YGR255C) 94.7 2 308.6 6 X X X * * * * X
Coq4 (YDR204W) 66 1 X * * * * X
Cat5 (YOR125C) 124.6 2 85 1 X X X * * * X
Coq1 (YBR003W) 79 3 251.9 14 X X X X * * * X
Bat1 (YHR208W) 1808.9 19 1285.8 19 X X X X X X * * * X
Bat2 (YJR148W) 606.4 4 X X *
Ilv2 (YMR108W) 6884.7 38 4217.3 41 X X X X X X X * * * X
Ilv6 (YCL009C) 1554.2 26 858.8 11 X X X X X * * * * X
Ilv5 (YLR355C) 4519.7 35 8530.9 52 X X X X X X X * * * X
Leu4 (YNL104C) 5142.5 34 2088.1 30 X X X X X X
Ecm31 (YBR176W) 101.4 4 X X X * * 
Lys4 (YDR234W) 889.7 10 698.5 13 X X X X * * * * X
Ilv3 (YJR016C) 1079 15 1239.2 15 X X X X X X * * * * X
Atp11 (YNL315C) 307 3 480.3 5 X X X X * * * * X
Atp12 (YJL180C) 913.4 8 588.8 12 X * * * * X
Fmc1 (YIL098C) 66 4 X X X * * X
Bcs1 (YDR375C) 113 2 172.5 4 X X X * X
Mtm1 (YGR257C) 75 1 * X
Afg3 (YER017C) 371.6 8 609 15 X X X X * * * * X
Yta12 (YMR089C) 333.4 7 851.6 19 X X X X * * * X
Msp1 (YGR028W) 139.7 2 572.3 5 X X X X X
Hmg2 (YLR450W) 52 1 43.7 2 * * 
Mba1 (YBR185C) 83 1 42 1 X X X X * * * * X
Sry1 (YKL218C) 61.5 1
Emi5 (YOL071W) 227.4 2 608.8 4 X X X * * X
Hfa1 (YMR207C) 222 5 X X * X
Cem1 (YER061C) 101.5 1 73 3 X * * X
Ggc1 (YDL198C) 344.6 5 594.5 12 X X X X X * X
Mmf1 (YIL051C) 175.7 1 1397.6 14 X X X X X * * * * X
Abf2 (YMR072W) 119.2 4 258.6 8 X X X X X * * X
Taz1 (YPR140W) 188.3 4 X X * X
Yjr100c (YJR100C) 289.4 4 X X * * * 
Ylr253w (YLR253W) 93.5 1 82.3 2 X * * * *
Mcx1 (YBR227C) 303.2 8 X X X * * * X
Mge1 (YOR232W) 588.4 9 724.8 12 X X X X X X * * * * X
Ssc1 (YJR045C) 8246.6 74 9232.3 69 X X X X X X * * * * X
Hsp60 (YLR259C) 10136.1 49 10997.5 75 X X X X X X X * * * X
Hsp78 (YDR258C) 2702.5 22 2335.6 39 X X X X X * * * X
Hsp10 (YOR020C) 1478.6 14 1259.8 19 X X X X X X * X
Pim1 (YBL022C) 953.4 15 1631.4 29 X X X X X * * * X
7 Ubiquinone metabolism
10
Mitochondrial protein 
targeting
11
8
Branched chain amino 
acid biosynthesis
9
Respiratory Chain 
Complex assembly 1
14
15 Matrix protein import
12 Fatty acid biosynthesis
13
Tam41 (YGR046W) 127.3 3 * * * X
Mdj1 (YFL016C) 1387.9 12 606.7 10 X X X X * * * X
Tim21 (YGR033C) 93 1 165.7 2 X X * * * X
Pbp1 (YGR178C) 122.5 1 X X
Tim8 (YJR135W-A) 324.2 5 69 1 X X X X
Mrs5 (YBR091C) 70 1 X X * X
Tim54 (YJL054W) 192.1 3 672.1 12 X X X X X
Tim13 (YGR181W) 446 5 584.3 2 X X * X
Pam18 (YLR008C) 106 1 131 1 X X X * X
Tim22 (YDL217C) 133.2 1 44 1 X X * * X
Tim23 (YNR017W) 450.6 4 250.5 2 X X X X X * X
Pam16 (YJL104W) 994.5 5 172.1 4 X X X * X
Tim44 (YIL022W) 1754.2 19 2117.3 28 X X X X X X * * * X
Tim50 (YPL063W) 663 11 649.2 19 X X X X X * * * X
Mrs11 (YHR005C-A) 775.6 7 245 3 X X X
Tim17 (YJL143W) 98 2 81.8 2 X X * X
Tim9 (YEL020W-A) 829.5 6 523.9 3 X X X X X
Tim18 (YOR297C) 58 2 X X X * * * X
Ppa2 (YMR267W) 108.8 2 291.8 9 X X * * X
Ydr493w (YDR493W) 50.5 1 184.7 3 X X * 
Ecm19 (YLR390W) 106.4 5 X
Pet100 (YDR079W) 244.2 2 X X * * X
Acn9 (YDR511W) 323.9 4 391.1 8 X X * * * * X
Emi1 (YDR512C) 66 1 70.5 2
Lys12 (YIL094C) 1185.4 13 783.5 11 X X X X X X * * * X
Hem1 (YDR232W) 139.5 6 196.3 8 X X X * * * * X
Grs1 (YBR121C) 148.7 2 321.4 7 X X X X
Isa2 (YPR067W) 147 1 X X X * * * * X
Nfs1 (YCL017C) 797.5 10 1047.2 13 X X X X * * * * X
Cox15 (YER141W) 254.6 3 52.3 4 X X X X * * * X
Yfh1 (YDL120W) 142 1 249.2 6 X X X * * * X
Grx5 (YPL059W) 380.5 4 648.2 9 X X X X X * * X
Ssq1 (YLR369W) 253.4 7 930.2 14 X X X X * * * * X
Isu2 (YOR226C) 80.5 2 * * * X
Arh1 (YDR376W) 72 1 212.2 5 X X X X * * * * X
Jac1 (YGL018C) 179 2 274 3 X X * * * * X
Isu1 (YPL135W) 93.5 1 102 2 X * * * * X
Nfu1 (YKL040C) 341.2 4 152.5 4 X X X X * * * X
Glo4 (YOR040W) 134.8 3 X X X X * * * X
Tdh3 (YGR192C) 900.2 12 617.2 9 X X X X * 
Mrc1 (YCL061C) 75 1
Kar2 (YJL034W) 1247.2 16 845 16 X X * *
Sss1 (YDR086C) 102.3 1 80.7 1 * *
Sec63 (YOR254C) 104 2 358.3 6 X X X *
18
19
16 Tim23/Tim22 complex
17 Unknown module 2
22 Secretory pathway
20
Iron-sulfur cluster 
assembly
21
Ubp16 (YPL072W) 42 1 156.7 2 X X
Ymr098c (YMR098C) 41 1 282.9 5 X * *
24 Glutamine family Ctp1 (YBR291C) 98 1 93.3 2 X X X X * X
Cbp3 (YPL215W) 306.6 4 586.3 9 X X X X * * * * X
Cbp4 (YGR174C) 77.7 2 290.3 6 X X X X X * * X
Bna3 (YJL060W) 118.7 3 X X * * * 
Yil077c (YIL077C) 327.6 5 426.3 9 X *
Agx1 (YFL030W) 272.9 3 443 11 X X X X *
Cox16 (YJL003W) 70 1 96 2 X X * * X
Ylr281c (YLR281C) 73 1 * * 
Ylr290c (YLR290C) 53 1 73.3 2 X * *
Jid1 (YPR061C) 43.5 1 *
Atp10 (YLR393W) 88.7 2 175.3 3 X X X * * * X
Ylr091w (YLR091W) 57 1 X X *
Mdm38 (YOL027C) 1209 8 1235.9 22 X X X X * * X
Sls1 (YLR139C) 102.3 3 97 6 X X * * * X
Ymr166c (YMR166C) 50 1 * X
Lsp1 (YPL004C) 1285.1 11 1076.4 16 X X X X X X
Ape2 (YKL157W) 659.4 12 1682 21 X X X X * * * 
Yhm2 (YMR241W) 1501.7 6 587 7 X X X X X * X
Oac1 (YKL120W) 116.2 3 X X X X X * X
Psd1 (YNL169C) 387.1 5 402.7 5 X X X X * * * X
Tsc13 (YDL015C) 66 1 X X X *
Ayr1 (YIL124W) 128.5 1 205.3 2 X X X X X *
Mse1 (YOL033W) 191.4 3 X X * * * * X
Alt1 (YLR089C) 520.9 7 1179.7 16 X X X X X * * *
Put2 (YHR037W) 1030.4 13 974.3 17 X X X X X * * X
Oms1 (YDR316W) 415.1 4 357.8 8 X * * * *
Oxa1 (YER154W) 303.3 3 322.6 2 X X X X * * * * X
Oma1 (YKR087C) 469.3 1 * * X
Tfc3 (YAL001C) 48 1 X X X *
Itc1 (YGL133W) 43 1 111.7 3
Sac1 (YKL212W) 134.2 3 122.6 4 X X X X
Csf1 (YLR087C) 40 3 X X *   
Mgm101 (YJR144W) 865.1 8 552.2 9 X X X * * * X
Rim1 (YCR028C-A) 896.8 10 1749.8 17 X X X X X * * * X
Vas1 (YGR094W) 119.8 3 403.9 15 X X X * * * X
Pdb1 (YBR221C) 837.3 14 2202.2 23 X X X X X X X * * * * X
Prx1 (YBL064C) 680.6 13 1213.3 18 X X X X X * * * X
Mae1 (YKL029C) 730.8 17 672 12 X X X X X * * * * X
Tcm62 (YBR044C) 85 2 369.7 7 X X X X * * * * X
Pdx1 (YGR193C) 676.1 9 431.2 9 X X X X X * * X
Cym1 (YDR430C) 156.4 5 1105 21 X X X X * * 
Lpd1 (YFL018C) 3974.6 47 X X X X X X * * * X
23
27 Unknown module 1
28
Respiratory Chain 
Complex assembly 2
25
26
31 Glutamate biosynthesis
32
29
30
Mitochondrial/cytoplasmi
c lipid metabolism
35 Response to DNA damage
37
Pyruvate/α-ketoglutarate 
dehydrogenase 
33
34
Pda1 (YER178W) 1350.1 16 1902.1 19 X X X X X X X * X
Lat1 (YNL071W) 973.6 16 1662.4 14 X X X X X X * * * * X
Kgd1 (YIL125W) 4400.8 50 4342.7 51 X X X X X X X * * X
Kgd2 (YDR148C) 2818.2 18 3270.3 27 X X X X X X * * * * X
Xdj1 (YLR090W) 169 3 56.3 2 X
Ygr021w (YGR021W) 139 3 X * * *
Cox23 (YHR116W) 240 1 83 1 X
Ynl168c (YNL168C) 229.2 2 128.4 3 X X X * * * 
Nit3 (YLR351C) 195.4 4 X X * 
Adk1 (YDR226W) 67 2 140.2 3 X X X X
Mam33 (YIL070C) 964.3 12 1028.9 11 X X X X * * X
Adk2 (YER170W) 303.4 4 172.6 5 X X * X
42 Nam8 (YHR086W) 47 1 X
Cpr3 (YML078W) 1725.9 12 1633.2 16 X X X X X * * * X
Ydl027c (YDL027C) 92 1 X * *
Etr1 (YBR026C) 814.7 12 440.5 12 X X X X X * * X
Pil1 (YGR086C) 1642.8 12 1509.3 13 X X X X X X * 
Scs2 (YER120W) 69 1 375 4 X
Num1 (YDR150W) 89 2 X X
Gcv1 (YDR019C) 1025.8 17 310.7 7 X X X * * * X
Fol1 (YNL256W) 53 1 X X * * X
Shm1 (YBR263W) 842.5 8 1288.1 18 X X X * X
Mis1 (YBR084W) 386.3 9 1038.4 17 X X X X * * * * X
Gcv2 (YMR189W) 1389.9 13 277.3 12 X X X X X X * * * * X
Gcv3 (YAL044C) 1033.5 5 523.9 6 X X X X X * * * X
Ybr262c (YBR262C) 177.8 3 633.2 5 X X X * 
Ygl226w (YGL226W) 84.3 2 X * * *
Cds1 (YBR029C) 56 1 X
Gpd1 (YDL022W) 83.5 2 152.8 3 *
Gut2 (YIL155C) 3866.8 38 3118.9 46 X X X X X X X * * * X
Pgs1 (YCL004W) 81 2 * * * * X
Gut1 (YHL032C) 157.3 2 * * * 
Gpd2 (YOL059W) 87 1 X X * * * 
Tom70 (YNL121C) 1323.1 13 1610.5 29 X X X X X X * * X
Tom22 (YNL131W) 1025 6 1405.8 16 X X X X X X
Tom5 (YPR133W-A) 119.3 2 341.5 5 X X X X X
Tom40 (YMR203W) 1293.1 16 750.2 8 X X X X X X X X
Tom6 (YOR045W) 291.3 2 61.3 3 X X X
Sam50 (YNL026W) 450 2 233 2 X X X X X X * X
Sam37 (YMR060C) 136.3 2 52 1 X X X X
Sam35 (YHR083W) 195.4 3 40 1 X X X X X
Tom71 (YHR117W) 278.7 4 523.7 9 X X X X X * X
Tom7 (YNL070W) 363.3 3 X X X X X
Tom20 (YGR082W) 659.7 6 709.2 12 X X X X X X X
41 DNA replication
43
38
40
47
48 Glycerol metabolism
45
Cytoplasmic lipid 
metabolism
46
Folate and glycine 
metabolism
49 TOM complex
Mrh1 (YDR033W) 294.9 3 108 1 X X X
Pst2 (YDR032C) 104.5 1 314.6 4 X X X X X
Arg8 (YOL140W) 145.3 2 92 3 X X X X * * * X
Ecm40 (YMR062C) 246.4 6 510.9 8 X X X X X * * X
Arg5 239.9 5 530.8 10 X X X X * * * * X
Lap3 (YNL239W) 58.5 1 761.9 7 X X X * * * *
Imp2' (YIL154C) 49 1
Msk1 (YNL073W) 75.5 1 95 5 X X X * * X
Zim17 (YNL310C) 152.8 2 X X X
Gsc2 (YGR032W) 417.2 10 X
Fks1 (YLR342W) 533.3 11 X X X *
Fen1 (YCR034W) 42 1 106 1
Gas1 (YMR307W) 545.5 6 153.3 5 X X X *
Yal046c (YAL046C) 57.5 1 119 1 * * 
Pho88 (YBR106W) 146.7 3 271.8 5 X X X X
Cyc3 (YAL039C) 274.2 4 188.3 7 X X X
Hem15 (YOR176W) 102.3 2 172.7 6 X X X X X * * * * X
Hem14 (YER014W) 59 1 290.3 4 X X X X * * * * X
57 Ftr1 (YER145C) 966.1 3 275.5 2
Vph1 (YOR270C) 97 1 179.7 3
Tfp1 (YDL185W) 103.8 5 40 2 X X X
Vma2 (YBR127C) 46 1 X
Ygr012w (YGR012W) 313.9 5 190 4 X X X X * 
Yor251c (YOR251C) 43 1 185 4 X X
60 Yml030w (YML030W) 207.3 3 395.2 10 X X X X
Mss18 (YPR134W) 467.6 4 X X X
Mrs1 (YIR021W) 246.8 3 X X X * X
Mto1 (YGL236C) 170 3 410.3 8 * * * X
Mrs4 (YKR052C) 90 2 X X * * X
Nam2 (YLR382C) 175.7 5 875.5 14 X X * * X
Mtf2 (YDL044C) 83.5 1 574.2 8 X X * * X
Slm3 (YDL033C) 98 1 131 3 X * * * X
Mss116 (YDR194C) 392.1 6 1166.2 27 X X X X * * X
Pet112 (YBL080C) 386.1 6 X X * * * X
Aep1 (YMR064W) 194 2 * 
Aep2 (YMR282C) 107 1 221.5 4 X X * * * * X
Mss51 (YLR203C) 239.3 4 459.6 12 X X X X X * * * X
Pet309 (YLR067C) 40 2 X X  * *  * X
Cbp6 (YBR120C) 235.6 3 X X X * X
Dss1 (YMR287C) 41 1 164.2 6 X X * * X
Pet494 (YNR045W) 80 2 X X * X
Sov1 (YMR066W) 133 1 98 1 X X * * * 
Pet111 (YMR257C) 67 1 X X * * * X
Pet54 (YGR222W) 204.6 3 463.7 8 X X X * * X
51 Arginine biosynthesis
52
50
55
56
53
54
Cell wall organisation and 
biogenesis
61 RNA splicing
62
Translation regulator 
activity
58 Vacuolar acidification
59
Cox20 (YDR231C) 470 3 490.6 5 X X X X
Odc1 (YPL134C) 286.2 6 515.9 9 X X X X X * X
Ybr269c (YBR269C) 593.4 4 516.4 9 X X X * * * 
Mgm1 (YOR211C) 332.7 4 860.8 14 X X X X X * * * X
Fzo1 (YBR179C) 218 3 X X X X X * X
Fis1 (YIL065C) 156 1 397 3 X X X X X X X X
Ugo1 (YDR470C) 100.5 2 221.4 5 X X X X * X
Mdv1 (YJL112W) 167.7 2 100.3 5 X X X
Pus4 (YNL292W) 79.5 2 X
Ifm1 (YOL023W) 141.4 4 173.5 4 X X * * * * X
Mst1 (YKL194C) 121.7 2 221.7 4 X X * * * X
Dia4 (YHR011W) 218.5 1 302.5 5 * * * X
Ilv1 (YER086W) 1874.8 14 1052.3 15 X X X X * * * X
Cha1 (YCL064C) 404.1 5 122.7 2 X X X * * * * X
Mef1 (YLR069C) 1112.9 14 1296.7 17 X X X X * * X
Mef2 (YJL102W) 261.6 3 118.5 2 X X * * 
Tuf1 (YOR187W) 2689.6 35 2934.4 23 X X X X X X * * * * X
Qri7 (YDL104C) 341.7 4 120.3 3 X * * * 
Ydl119c (YDL119C) 41 1 X * * X
Sco2 (YBR024W) 162.7 3 191 3 X X X * * * X
Cox11 (YPL132W) 45 1 95 1 X X X * * * X
Sco1 (YBR037C) 88.7 2 229.3 4 X X X X X * * * * X
Tat1 (YBR069C) 104 2
Dug1 (YFR044C) 438.5 8 X X X
Mir1 (YJR077C) 3406.8 32 991.9 12 X X X X X X X * * X
Cyc1 (YJR048W) 1179.7 8 843.3 8 X X X X X * * X
Osm1 (YJR051W) 46 1 217.3 4 X X * * X
Ccp1 (YKR066C) 426.8 9 744.4 16 X X X X X X * * * X
72 Nuc1 (YJL208C) 157 3 155.6 3 X X X X X X X
73 Pkp1 (YIL042C) 95 1 X X X * * * * X
74 Nat2 (YGR147C) 149 1 190.3 3 X X * * * *
Erg6 (YML008C) 1142.3 11 895.5 13 X X X X X
Faa1 (YOR317W) 489.9 5 460.3 7 X X X X X X * 
Eht1 (YBR177C) 186 2 304.8 7 X X X X
Ygl059w (YGL059W) 193.5 3 X * * 
Yjl161w (YJL161W) 40 1 X X *  * *  *
Ynl100w (YNL100W) 42 1 332.2 7 X X X X *
Ydl157c (YDL157C) 50 1 X X * 
Mrf1 (YGL143C) 186.8 4 X X * * * X
Sua5 (YGL169W) 86.5 1 * 
Mrpl13 (YKR006C) 483.3 9 763.5 10 X X * * * X
Mrpl32 (YCR003W) 90.5 1 70.5 4 X X X * X
Mrpl49 (YJL096W) 347.4 3 253.8 3 X X X * X
Mrpl50 (YNR022C) 43 1 80.5 2 X X * X
65
66 Amino acid metabolism
63
64 Fusion/fission
69
Respiratory Chain 
Complex-IV assembly
70
67
68
76
77
71
75
78
Mrpl31 (YKL138C) 50 1 89.5 1 X * * * X
Bud3 (YCL014W) 40 3   
Mnp1 (YGL068W) 810 8 881.9 11 X X X X X * * * * X
Mrpl16 (YBL038W) 129.8 4 X X * * * * X
Img2 (YCR071C) 106.2 4 X X * * * X
Mrp49 (YKL167C) 71.7 3 X X X * * * X
Mrp20 (YDR405W) 138 3 74.6 3 X X X X * * * X
Mrpl24 (YMR193W) 263.8 3 497.1 6 X X X * * * X
Yml6 (YML025C) 267.7 7 488.7 11 X X X * * * X
Mrh4 (YGL064C) 143 4 X X X * * X
Mrpl3 (YMR024W) 545.2 6 297.1 6 X X X X X * * * * X
Mrpl19 (YNL185C) 259.4 2 X X X X X
Mrpl17 (YNL252C) 309.1 5 815.4 13 X X X X X * * * * X
Mrpl37 (YBR268W) 164.5 1 41 1 X X * * * X
Mrpl36 (YBR122C) 177.4 2 848.4 8 X X X
Mrpl25 (YGR076C) 115.7 2 81.7 3 X X X * X
Mrpl10 (YNL284C) 98 2 209.3 5 X X X * * X
Mrpl27 (YBR282W) 203.8 2 110.4 2 X X * * X
Mrpl8 (YJL063C) 199.1 4 413.7 6 X X X * X
Mrpl15 (YLR312W-A) 196.3 2 273.1 2 X X X * X
Mrpl28 (YDR462W) 76.5 2 87 1 X X X X * * * X
Mrpl7 (YDR237W) 58 1 154.3 2 X X X * * X
Mhr1 (YDR296W) 113 1 234.6 3 X X X X * * * X
Mrpl4 (YLR439W) 110 1 486.5 6 X X X X * * X
Mrpl44 (YMR225C) 352.8 1 587.8 4 X X * * * * X
Mrpl51 (YPR100W) 329.5 4 218.1 5 X X X * * * X
Mrpl38 (YKL170W) 279.1 4 X X * X
Mrp7 (YNL005C) 650.2 6 412.3 8 X X X * X
Mrpl35 (YDR322W) 478.6 5 461.2 9 X X X X * * * * X
Rml2 (YEL050C) 232.4 2 169.8 3 X * * * X
Mrpl33 (YMR286W) 211.4 4 65 1 X X X * * * * X
Img1 (YCR046C) 106.7 3 258.6 5 X X X * * * * X
Mrpl40 (YPL173W) 431.3 6 781.5 13 X X X X X X
Mrpl1 (YDR116C) 248.3 4 373.8 8 X X X * * X
Mrpl6 (YHR147C) 276.6 3 114.3 5 X X X X * * * * X
Mrpl11 (YDL202W) 500.6 9 765.2 7 X X X * * * X
Mrpl23 (YOR150W) 113 2 41 1 X X * X
Mrpl22 (YNL177C) 461 3 367.9 6 X X X * * X
Mrpl20 (YKR085C) 202.8 3 261.7 4 X X X * * * X
Mrpl9 (YGR220C) 245.4 4 140.1 3 X X X X * * * X
Msd1 (YPL104W) 59 2 378.3 10 X X X X * * * X
Msy1 (YPL097W) 341 4 563.4 8 X X X * * * * X
Msf1 (YPR047W) 264 4 76.4 6 X X * * X
Aat1 (YKL106W) 111.3 2 X X X * * * * X
80 tRNA aminoacylation
79
Components of the large 
subunit of mitochondrial 
ribosomes-MRPL
Aat2 (YLR027C) 135 2 101 1 X *
Sod1 (YJR104C) 632.6 6 819.4 7 X X X X X
Sod2 (YHR008C) 1792.3 11 X X X X X X * * * * X
82 Hir2 (YOR038C) 74 2 *
Yme2 (YMR302C) 580.4 11 801 15 X X X X X * * * * X
Yme1 (YPR024W) 1881.3 17 943.1 20 X X X X * * * X
Rex2 (YLR059C) 57 1 X X * * * X
Msr1 (YHR091C) 50 1 161.2 7 X X * * * X
Ism1 (YPL040C) 40 1 339.9 6 X X * * * * X
85 Ecm33 (YBR078W) 1114.6 8 187.8 1 X X X * * * *
86 Ptc5 (YOR090C) 56 1 99 7 X X * X
Yer078c (YER078C) 66.5 1 279.6 5 X X * * * 
Rim2 (YBR192W) 75.5 2 X X * X
89 Mia40 (YKL195W) 1040.2 13 985.7 15 X X X X X * X
90 Yhl021c (YHL021C) 310.4 3 675 15 X X X X X * * X
Yor285w (YOR285W) 157.7 1 165.3 4 X X X X
Dpm1 (YPR183W) 108.8 3 265.6 4 X X X X
92 Cdc9 (YDL164C) 43 1 206 4 * * * X
Por1 (YNL055C) 8606.7 58 4139.2 34 X X X X X X X * * X
Cyc2 (YOR037W) 48 2 X X * X
Por2 (YIL114C) 96.5 1 63 1 X X X X X X
94 Sec4 (YFL005W) 85.5 1 163.2 4 X X X X X *
Mdh1 (YKL085W) 4833.9 35 2964.2 36 X X X X X X X * * X
Yor356w (YOR356W) 202.7 4 589.1 10 X X X X X * * X
Cyb2 (YML054C) 1738.5 18 1735 25 X X X X X X * * X
Fum1 (YPL262W) 2081.4 25 1695.3 17 X X X X X * * * X
Ygr207c (YGR207C) 236.6 5 336.3 10 X X X X * * X
Dld1 (YDL174C) 1701.7 24 1752.6 32 X X X X X X * * * X
Cit2 (YCR005C) 450.8 6 784.7 7 X X X X *
Ndi1 (YML120C) 1911.7 24 2467.9 31 X X X X X X * * * X
Nde2 (YDL085W) 685.5 11 628.4 10 X X X X X * * * * X
Cit3 (YPR001W) 113.4 3 348.9 9 X X X * * * X
Ypr004c (YPR004C) 1200.6 8 585.8 7 X X X X * * * 
Cit1 (YNR001C) 3480.1 35 5102.5 46 X X X X X X * * * X
Nde1 (YMR145C) 2221.8 27 1390.4 23 X X X X X X X * * * X
Atm1 (YMR301C) 322.5 6 X X X * * * * X
Mdl2 (YPL270W) 446.5 9 389.7 8 X X X X
Mdl1 (YLR188W) 194.8 4 599.9 9 X X X * * * X
Pet127 (YOR017W) 71 1 261.5 5 X X * * * X
Cbp2 (YHL038C) 48 1 161.8 2 * X
98 tRNA/rRNA processing Rpm2 (YML091C) 51 1 204 3 X X X * * X
Mrps28 (YDR337W) 360.3 6 800 12 X X X X * * * * X
Mrps17 (YMR188C) 194.7 4 434.7 6 X X X * * X
Mrp4 (YHL004W) 249.2 3 619 12 X X X X * * * * X
81
87
91
83
84
96
97
93
95
NAD metabolism/TCA 
cycle
Rsm18 (YER050C) 63.5 2 123 2 X X X * * * X
Rsm10 (YDR041W) 189.6 3 548.7 9 X X X * * * * X
Mrp51 (YPL118W) 161.7 3 282.5 8 X X X * X
Ymr31 (YFR049W) 819.2 5 184.2 3 X X X X * * * * X
Mrps18 (YNL306W) 292.3 3 477.1 8 X X X X X * * * X
Mrps16 (YPL013C) 59 2 X X * * * * X
Rsm25 (YIL093C) 269.9 5 749.1 10 X X X X X
Mrps9 (YBR146W) 375.8 7 X X X * * * X
Ehd3 (YDR036C) 388.7 9 743.4 8 X X X * * * 
Mrps8 (YMR158W) 397.1 3 97.4 3 X X X * * X
Pet123 (YOR158W) 462.2 4 760.5 14 X X X X * * * X
Mrp17 (YKL003C) 386.6 6 X X * X
Mrps35 (YGR165W) 485.4 8 347.2 8 X X * * * X
Ynr036c (YNR036C) 363.7 2 225.2 3 X * * * X
Fyv4 (YHR059W) 94 1 * *
Rsm26 (YJR101W) 460.5 5 X X X X * * X
Mrp1 (YDR347W) 737.4 7 965.1 7 X X X X X * * * * X
Mrp10 (YDL045W-A) 80.5 1 X
Rsm22 (YKL155C) 177.4 4 618.1 10 X * * * X
Rsm7 (YJR113C) 181.7 5 384.7 6 X X X * * * X
Rsm27 (YGR215W) 200.5 1 145.8 3 X X X X
Yor205c (YOR205C) 82.7 2 111.2 5 X X * * * *
Mrp21 (YBL090W) 123 2 423.4 5 X X * * * X
Mrps5 (YBR251W) 163.6 4 348.8 12 X X X * * X
Rsm23 (YGL129C) 265.6 5 613.4 13 X X X * X
Rsm24 (YDR175C) 269.1 6 742.9 10 X X X X * * * X
Nam9 (YNL137C) 285 4 593.1 12 X X X X * * X
Ygr150c (YGR150C) 255.8 2 159.1 8 X * * *
Mrp13 (YGR084C) 248.7 2 202.1 6 X X X * * X
Sws2 (YNL081C) 50 1 * * X
100 Yor286w (YOR286W) 49 1 272.2 5 X X X * * * 
101 Guf1 (YLR289W) 82.5 1 400.5 7 * * * X
Leu5 (YHR002W) 136 1 X * X
Leu9 (YOR108W) 2682.5 18 399 13 X X X * X
Acs1 (YAL054C) 43 1 115.5 3 X X
Adh3 (YMR083W) 252.3 4 765.1 16 X X X X X X * * * X
Ach1 (YBL015W) 3393.2 33 3499.1 48 X X X X X X * * X
Adh4 (YGL256W) 116.5 2 X * *
Ald5 (YER073W) 1499.9 20 2307 28 X X X X * * * X
Ald4 (YOR374W) 10956.2 74 15669.4 113 X X X X X X * * * X
Acs2 (YLR153C) 44 1
Sfc1 (YJR095W) 486 12 449.8 6 X X X X * X
Jen1 (YKL217W) 563.3 6 181.5 2 X X X
Cox14 (YML129C) 380 3 162 2 X X X X * * X
103
Alcohol/aldehyde 
dehydrogenase
104
99
Components of the small 
subunit of mitochondrial 
ribosomes-MRPS
102
106
Shy1 (YGR112W) 423.3 6 137.4 3 X X X X * * * X
Mss2 (YDL107W) 131.8 3 * X
Pnt1 (YOR266W) 141.3 2 300.8 2 X * * * X
Acp1 (YKL192C) 363.6 4 251.3 2 X X X X * * * X
Hts1 (YPR033C) 128.3 2 247.5 7 X * * * * X
Icl2 (YPR006C) 383.8 8 841.3 17 X X X X X * * X
Om45 (YIL136W) 5321.4 46 4383.5 45 X X X X X X X
Pdh1 (YPR002W) 912.1 18 699.9 16 X X X X X X * *
110 Yor022c (YOR022C) 72 1 X * * * 
Trr2 (YHR106W) 207 2 222.3 3 X * * * * X
Trx3 (YCR083W) 145 2 69 2 X X X * * * X
Glr1 (YPL091W) 209.6 4 X X X * * 
113 Bio2 (YGR286C) 56 1 112.3 3 X * * * * X
Ypr011c (YPR011C) 42 1 59 1 X X
Yfr045w (YFR045W) 59 1 85 1 X * X
Sal1 (YNL083W) 59 1 X X X
Agc1 (YPR021C) 172.8 5 X X X * X
Crc1 (YOR100C) 138.7 2 117 1 X X X * X
Hmi1 (YOL095C) 95 1 X X * X
Ydr332w (YDR332W) 319.3 5 * * *
117 Pet117 (YER058W) 82.8 3 X * X
118 Mtg2 (YHR168W) 178.3 1 72 1 * * X
Mmt1 (YMR177W) 134 2 X X X * * * X
Mmt2 (YPL224C) 45 1 X X X * * * X
120 Stf1 (YDL130W-A) 1299.5 4 390.7 4 X X X * * * * X
Fmp45 (YDL222C) 162 3 X X X *
Ptc7 (YHR076W) 85 2 354.4 6 X X X * * * * X
122 Yir024c (YIR024C) 71.3 5 X X * * *
123 Cat2 (YML042W) 492.6 12 802.9 18 X X X X X * X
Ato3 (YDR384C) 77.3 4 X X
Ato2 (YNR002C) 189 3 X X * *
126 Rmd9 (YGL107C) 401.9 3 966.2 13 X X X * * * * X
Mct1 (YOR221C) 87 2 117.6 3 X X * * X
Oar1 (YKL055C) 52 1 * X
Gtt1 (YIR038C) 47 1 99 3 X X X X X
Grx2 (YDR513W) 280.9 3 91.3 2 X X X X
129 Msw1 (YDR268W) 59 1 179.3 4 X X X * * * * X
130 Pth2 (YBL057C) 225.6 3 215.8 2 X X X * * *
Mas2 (YHR024C) 576.3 11 1062.3 16 X X X X * * X
Mas1 (YLR163C) 604.3 9 880.8 8 X X X X X * * * * X
Rps18a (YDR450W) 78 1 88 2 X X X * *
Rpl23b (YER117W) 79 1 129 1 X X
Rps14a (YCR031C) 120.5 2 301.9 4 X X X *
Rpl9a (YGL147C) 89 1 X *
108
109
106
107
116
119
111
115 Transport
127
128
121
124
131
132 Cytoplasmic ribosome
Rps5 (YJR123W) 115 1 64 1 *
Rpl9b (YNL067W) 89 1 X *
Rps14b (YJL191W) 120.5 2 301.9 4 X X *
Rpl2b (YIL018W) 48 1 * 
133 Sun4 (YNL066W) 40 1   X
134 Pet9 (YBL030C) 1139.3 25 2221.8 30 X X X X X X * * X
135 Hnt2 (YDR305C) 139.8 4 X * *
136 Apn1 (YKL114C) 89 1 * X
Som1 (YEL059C-A) 103.5 1 X
Ylr218c (YLR218C) 71.5 1 123.5 2
Lip2 (YLR239C) 72 2 140 2 X X X * * X
Lip5 (YOR196C) 573.9 5 289.7 5 X X * * * * X
Tcb3 (YML072C) 136 5 420.6 9 X X X X
Pdr5 (YOR153W) 98.5 2 71 4 X X X
141 Ybl059w (YBL059W) 85.3 2 47.5 2 X
142 Scm4 (YGR049W) 48 1 X X X *
Ylr036c (YLR036C) 43 1
Pam17 (YKR065C) 123.3 1 270 3 X X X X X * * X
144 Cyt2 (YKL087C) 118.5 2 83.3 3 X X X
Fmt1 (YBL013W) 119 2 X X * * * X
Msm1 (YGR171C) 114 1 70 4 X X * * X
Lsc2 (YGR244C) 2263.6 26 3609.9 35 X X X X X X * * * X
Yjl045w (YJL045W) 416.3 7 X X X X *  * *  * X
Sdh3 (YKL141W) 72 1 284.1 2 X X X X X * * * X
Sdh4 (YDR178W) 287 4 382.5 6 X X X X X X * * * * X
Sdh2 (YLL041C) 1378.9 17 1225.9 13 X X X X X X X * * * X
Lsc1 (YOR142W) 2677.3 29 1575.8 10 X X X X X X * * * X
Sdh1 (YKL148C) 3781.6 44 1844.7 28 X X X X X X X * * * X
Mcr1 (YKL150W) 623.6 9 1002 15 X X X X X X X * * * X
Cbr1 (YIL043C) 94 2 41 2 X X X X * *
Aco1 (YLR304C) 6915.1 68 6785.7 71 X X X X X X * * X
Idp1 (YDL066W) 2761 25 4554.8 24 X X X X X X * * * X
Aco2 (YJL200C) 713.3 14 986.8 16 X X X X * * *
Idh1 (YNL037C) 3398.5 24 3662.9 33 X X X X X X * * * * X
Idh2 (YOR136W) 4756 30 3440.4 16 X X X X X X * * * * X
150 Hsc82 (YMR186W) 171.3 2 X X X X
Sac6 (YDR129C) 76.5 1
Dld2 (YDL178W) 497.8 13 733.9 12 X X X X X * * * X
154 Caf17 (YJR122W) 54 1 371.5 3 X * * 
Atp14 (YLR295C) 553.3 8 1023.6 11 X X X X * * * X
Atp6 (Q0085) 269.2 1 244 3 X X X X X
Atp7 (YKL016C) 1115.1 11 1099.4 12 X X X X X X X
Atp15 (YPL271W) 504.4 9 488.7 5 X X X X X * * X
Atp4 (YPL078C) 1400.7 17 1749.7 14 X X X X X X * * * X
137
138
132 Cytoplasmic ribosome
146
147
Respiratory Chain 
Complex-II 
140
143
153
148
149 Isocitrate metabolism
Tim11 (YDR322C-A) 975.4 7 543.9 7 X X X X X X
Atp19 (YOL077W-A) 45 1 X X X X
Atp1 (YBL099W) 7364.8 51 8990.7 59 X X X X X X * * * * X
Atp2 (YJR121W) 14609.9 71 11454.1 71 X X X X X X X * * * X
Atp16 (YDL004W) 835 11 691.1 8 X X X X X * * * X
Atp20 (YPR020W) 89.5 3 154.5 3 X X X X X * * * X
Atp5 (YDR298C) 1391.8 11 3080.3 20 X X X X X X X * * X
Atp17 (YDR377W) 111.2 3 70 1 X X X X X * * * X
Inh1 (YDL181W) 636.8 7 997.3 7 X X X X * * * * X
Atp3 (YBR039W) 2922.7 32 3590.7 33 X X X X X X X * * * * X
Atp18 (YML081C-A) 290.7 5 X X X X X * X
Qcr8 (YJL166W) 236.1 2 479.1 3 X X X X * X
Qcr2 (YPR191W) 5529.5 28 4012.1 45 X X X X X X X * * * X
Qcr6 (YFR033C) 263 5 121.8 4 X X X X X
Qcr10 (YHR001W-A) 137.8 2 257.4 4 X X X X X * * * X
Rip1 (YEL024W) 619.2 11 1847 25 X X X X X X * * * * X
Qcr9 (YGR183C) 158 1 140.3 2 X X * * X
Cor1 (YBL045C) 5052.4 46 3200.5 31 X X X X X X X * * * * X
Cyt1 (YOR065W) 3630.4 17 2548.7 18 X X X X X * * * X
Qcr7 (YDR529C) 1500.1 10 1283.3 16 X X X X X X X
Mtf1 (YMR228W) 58 1 242.8 4 X X
Rpo41 (YFL036W) 54 1 419.9 8 X X * * * * X
Pma1 (YGL008C) 5012.5 34 4100.1 34 X X X X
Pma2 (YPL036W) 3140.4 22 X X X X   
Hxt7 (YDR342C) 401.8 8 420.1 6 X X X
Hxt6 (YDR343C) 601.3 10 402.3 5 X X X
Efb1 (YAL003W) 93 1
Tif3 (YPR163C) 44 1 X
Pct1 (YGR202C) 43 1 * 
Ypr115w (YPR115W) 43 1 X
Tes1 (YJR019C) 100 2 X X X *
Wwm1 (YFL010C) 276.5 2 X X
Acb1 (YGR037C) 42 1 * 
Nop9 (YJL010C) 42 1 *
Pfk2 (YMR205C) 42 1 X *
Asi3 (YNL008C) 40 1 * 
Sir3 (YLR442C) 42 1 X X *
Shr3 (YDL212W) 42 1   
Atg11 (YPR049C) 42 1
Ydr286c (YDR286C) 43 2 * * *
Hmx1 (YLR205C) 56 1 133 1
Ynl247w (YNL247W) 95 3 * * 
Dpb4 (YDR121W) 85.5 2
Bud21 (YOR078W) 42 1 * 
155
Respiratory Chain 
Complex-V
158
160
156
Respiratory Chain 
Complex-III
157
Rps13 (YDR064W) 42.5 1 X X *
Spo73 (YER046W) 50 1 *
Tdh1 (YJL052W) 787.5 11 586.6 7 X X * 
Ant1 (YPR128C) 406.4 3 92 1 * *
Rsc30 (YHR056C) 319 4 74 1
Ypr091c (YPR091C) 56 1 253.6 6
Nbp1 (YLR457C) 50.5 1
Rpl31b (YLR406C) 49 1 *
Yil055c (YIL055C) 45 1
Utp8 (YGR128C) 50 1 * 
Ygl057c (YGL057C) 50 1 X * * * *
Yhl018w (YHL018W) 50 3 * *
Cdc19 (YAL038W) 54 1 * 
Rpl21a (YBR191W) 52.7 2 * *
Ioc2 (YLR095C) 55 1 * 
Ubc6 (YER100W) 75.5 1
Cdc33 (YOL139C) 54 1 * 
Idp2 (YLR174W) 560.8 6 396.5 3 X X
Nup49 (YGL172W) 51.5 3 * 
Ydr070c (YDR070C) 53.5 2 X X X * * * X
Rps27a (YKL156W) 62 1
Rsn1 (YMR266W) 179.3 3 X
Ykl063c (YKL063C) 45 1
Mss4 (YDR208W) 45 1
Ebp2 (YKL172W) 48 1 *
Tif4631 (YGR162W) 45.5 1 X X
Dat1 (YML113W) 45.5 2
Htb1 (YDR224C) 115.8 2 93 3 X X X
Ydr282c (YDR282C) 50 1 * * *
Sen34 (YAR008W) 65 2 X X
Knh1 (YDL049C) 45 1
Sik1 (YLR197W) 41 2
Lpe10 (YPL060W) 48 1 * * * * X
Sil1 (YOL031C) 46 1 * 
Erg26 (YGL001C) 177.2 2 199.4 4 X
Rvs167 (YDR388W) 49 2 *  *  *
Nhp10 (YDL002C) 89 1
Rpl13b (YMR142C) 116 2 X * *
Nas2 (YIL007C) 46 2
Yil156w-b (YIL156W-B) 86 1
Yll029w (YLL029W) 46.5 1
Gpb2 (YAL056W) 46 1 *
Erp1 (YAR002C-A) 273.5 1 149 1 X X
Msc6 (YOR354C) 269.9 4 543.3 13 X X X * * 
Ynl054w-b (YNL054W-B) 334.5 5 * 
Taf12 (YDR145W) 288.1 4 * 
Erg28 (YER044C) 74.3 2 65 1 * 
Fbp1 (YLR377C) 86 2 67 1
Ist2 (YBR086C) 253.8 2 66 3 * 
Pmt1 (YDL095W) 248.2 2 131 1 X * 
Gpi17 (YDR434W) 51.5 1
Pom152 (YMR129W) 269.2 4 195.3 3 X X
Tra1 (YHR099W) 45 1 53 4
Rvb1 (YDR190C) 303.8 2 182.2 4 X *
Pgk1 (YCR012W) 348.6 7 219.2 4 X X X
Vps5 (YOR069W) 40 1    *
Ycl057c-a (YCL057C-A) 361.4 6 309.7 4 X X *
Ylr077w (YLR077W) 354.1 5 174.9 5 X X X * * *
Emp24 (YGL200C) 322 2 48 1 X *
Yer182w (YER182W) 210.3 4 62.5 2 X X X X X * * * X
Yel007w (YEL007W) 349 3
Cdc14 (YFR028C) 54 1 54 1
Rpp0 (YLR340W) 44 1 40 2 X
Taf10 (YDR167W) 350.6 3 68 2
Yor215c (YOR215C) 223 2 735.8 12 X X X X X * * 
Mdj2 (YNL328C) 113 1 * X
Eno1 (YGR254W) 247 5 176.2 3 X X
Rpl11b (YGR085C) 241.6 1 63.5 3 *
Cam1 (YPL048W) 133 1 * 
Rsc6 (YCR052W) 223.8 3 117.5 2
Hsp30 (YCR021C) 211.6 2
Sur4 (YLR372W) 211.3 3 176.3 1
Ykl207w (YKL207W) 64 1 *
Rsc2 (YLR357W) 217.3 1 152 3 * 
Abf1 (YKL112W) 215.3 3 70.5 2
Tpo1 (YLL028W) 213 3 * 
Yck2 (YNL154C) 241.2 3 50 1 X
Pcs60 (YBR222C) 156.4 6 203.5 1 X
Eno2 (YHR174W) 248 5 233 2 X
Nhp6b (YBR089C-A) 101.7 2 300 3 * *
Rpl11a (YPR102C) 241.6 1 63.5 3 *
Aep3 (YPL005W) 75 1 * * X
Hhf1 (YBR009C) 227.9 3 X X X
Hhf2 (YNL030W) 227.9 3 X X
Cue4 (YML101C) 240 1 158.5 1
Net1 (YJL076W) 238 1
Pet10 (YKR046C) 235.6 3 137.5 3 *
Erv1 (YGR029W) 450.5 4 596.6 4 X X X X
Dic1 (YLR348C) 40 1 X X X    * X
Spg1 (YGR236C) 41 1 X X *
Srp101 (YDR292C) 69 1 * *
Spa2 (YLL021W) 40 2 X
Yor084w (YOR084W) 883 6 93 1 * 
Yer080w (YER080W) 882.9 14 1263.6 20 X X X X X * * * 
Ynl208w (YNL208W) 882.9 7 329.9 3 X X
Ras2 (YNL098C) 1133.2 9 62 1
Tef2 (YBR118W) 896.9 16 450.6 13 X X * 
Abp1 (YCR088W) 61 1 * 
Snf6 (YHL025W) 41 1   
Ylr361c-a (YLR361C-A) 41 1
Ykl077w (YKL077W) 42 1
Gvp36 (YIL041W) 42 2 X
Snf2 (YOR290C) 41.3 3
Rgd2 (YFL047W) 40 1
Pnc1 (YGL037C) 97.5 1
Ynl146w (YNL146W) 40 1
Prp24 (YMR268C) 45 1
Arg81 (YML099C) 40.3 2   
Stb4 (YMR019W) 42 1 *
Hta2 (YBL003C) 493.7 6 128.3 2 X X * 
Slm5 (YCR024C) 464.1 6 321.8 6 X X * * X
Ai1 (Q0050) 120 3 X * X
Gas5 (YOL030W) 757.6 6 * * *
Ypt7 (YML001W) 523.7 6 X X
Bdf1 (YLR399C) 809.1 2 150.5 3
Ymr157c (YMR157C) 391.9 2 416 5 X X * * * 
Nce102 (YPR149W) 390.8 3 49 1 X X * 
Car2 (YLR438W) 81 1 173 2
Fox2 (YKR009C) 434.8 4 96.5 1 X *
Gpa2 (YER020W) 434.7 2 117.5 1 X X
Ctr1 (YPR124W) 417.4 5 159.6 4
Aro2 (YGL148W) 83 1
Yjr080c (YJR080C) 723.2 9 481.3 6 X X X X * *
Taf14 (YPL129W) 143.8 1
Opi3 (YJR073C) 50 1 X X
Pck1 (YKR097W) 772.6 7
Rsc8 (YFR037C) 610.1 5 268 2
Rpl26b (YGR034W) 80 1 * 
Yfr011c (YFR011C) 269.2 6 741.7 11 X X X X X
Pdi1 (YCL043C) 685.8 13 512.1 7 X X
Zeo1 (YOL109W) 669.9 7 122.5 6 X X X X *
Rpl19a (YBR084C-A) 98 2 233 2 X X * * *
Pdr12 (YPL058C) 924.1 11 X
Ynr018w (YNR018W) 221.3 5 166.4 6 X X X *
Jip4 (YDR475C) 112.3 2
Ies1 (YFL013C) 112.3 3
Rpl20b (YOR312C) 96.3 2 74 1 X * *
Ybl055c (YBL055C) 116 1 * * * 
Adr1 (YDR216W) 113 1
Htd2 (YHR067W) 110.5 1 X * X
Gnd1 (YHR183W) 108.3 4 X X
Vma22 (YHR060W) 121 1 * 
Erg5 (YMR015C) 111.5 2 * 
Gdi1 (YER136W) 42 1
Msc1 (YML128C) 110.7 2 X X X
Arn1 (YHL040C) 122.5 2
Yor164c (YOR164C) 107 1 * *
Yjl147c (YJL147C) 149 3 * * *
Did2 (YKR035W-A) 129.8 2
Ydl183c (YDL183C) 77.5 1 * * * *
Ymc2 (YBR104W) 126.5 1 X X X * * X
She10 (YGL228W) 135.3 4
Hnt1 (YDL125C) 118.6 4 X
Erv41 (YML067C) 117.5 1
Erg2 (YMR202W) 120.3 2 X * 
Caj1 (YER048C) 119 1 *
Ena1 (YDR040C) 296.2 3
Mip1 (YOR330C) 101 1 X X X
Rot2 (YBR229C) 100.5 2 X X X * 
Ssp120 (YLR250W) 44 2 * 
Pot1 (YIL160C) 102.5 1 * 
Rpl22a (YLR061W) 102 1 *
Ypt32 (YGL210W) 101.3 2 X *
Sps19 (YNL202W) 45 1
Nup157 (YER105C) 96 2 *
Sbp1 (YHL034C) 96 2
Ipp1 (YBR011C) 99 1 X *
Cmd1 (YBR109C) 99 1
Ioc4 (YMR044W) 98 1
Ybr159w (YBR159W) 50 1 59 1 * 
Npl6 (YMR091C) 69 1
Osh6 (YKR003W) 105 1
Ost2 (YOR103C) 107 1 *
Yck1 (YHR135C) 625.2 3 120.5 2 X X
Yor131c (YOR131C) 106 1 X X
Cyb5 (YNL111C) 103 2 X
Sgf29 (YCL010C) 66 1
Rpl12b (YDR418W) 102.7 3 X *
Rps9a (YPL081W) 121 1 143 2 * 
Rer1 (YCL001W) 104 1
Lys1 (YIR034C) 103 1 X * 
Sey1 (YOR165W) 203.2 4 * 
App1 (YNL094W) 200.6 3
Rco1 (YMR075W) 43 1
Eug1 (YDR518W) 207.2 3 X *
Rho3 (YIL118W) 56 1 64 1
Rpc19 (YNL113W) 204.3 3
Tcb2 (YNL087W) 183.6 3 X
Ecm37 (YIL146C) 181 1
Rps2 (YGL123W) 180.5 1 X *
Yer093c-a (YER093C-A) 198 4
Pan5 (YHR063C) 196.7 3 X
Sec11 (YIR022W) 190 2 * 
Ies6 (YEL044W) 73 1
Erv25 (YML012W) 257.8 6 X *
Hbt1 (YDL223C) 254.4 4 *
Pho84 (YML123C) 354.8 7 X
Ena5 (YDR038C) 296.2 3
Ena2 (YDR039C) 296.2 3 X X
Rpp2a (YOL039W) 232.8 3 X
Spf1 (YEL031W) 115.3 4 274.9 7 X X X
Fet3 (YMR058W) 225.2 2
Heh2 (YDR458C) 42 1
Trr1 (YDR353W) 243.3 2 * *
Ybl107c (YBL107C) 49 1 88.5 2
Rps4b (YHR203C) 136 3 X * * *
Rps4a (YJR145C) 136 3 X * * *
Gpa1 (YHR005C) 48 1 91.5 2 X
Ydl121c (YDL121C) 147.5 1
Yor1 (YGR281W) 139.5 4 X
Src1 (YML034W) 137 2
Rps10b (YMR230W) 51.5 1
Fus3 (YBL016W) 131 1 X X * 
Mne1 (YOR350C) 130.4 4 * * *
Hbn1 (YCL026C-B) 134 2
Sis1 (YNL007C) 226.6 3 149.5 3 *
Asc1 (YMR116C) 133 3 X
Rps28a (YOR167C) 50 1 51 1 * * *
Sec23 (YPR181C) 169.2 5 X
Yjl046w (YJL046W) 166 5
Rpl21b (YPL079W) 52.7 2 * * *
Ai2 (Q0055) 176 5 X * * X
Chd1 (YER164W) 175.5 2 X X
Ssa3 (YBL075C) 152.3 2 X
Ylr118c (YLR118C) 150.5 1 * 
Asi2 (YNL159C) 106 1
Rpl5 (YPL131W) 162 4 X X * 
Tal1 (YLR354C) 45 1 * 
Sed5 (YLR026C) 157 1
Vps21 (YOR089C) 95 2 X X X
Rps26a (YGL189C) 66 1
Trx2 (YGR209C) 66 1
Nat3 (YPR131C) 82 1
Yim1 (YMR152W) 67 2 X X X X
Yil083c (YIL083C) 75 1
Nup159 (YIL115C) 66.5 2
Tef1 (YPR080W) 896.9 16 450.6 13 X X X
Tef4 (YKL081W) 64 1 X X
Loc1 (YFR001W) 64 1 * 
Rtt102 (YGR275W) 378.7 3
Ptc6 (YCR079W) 66 2
Ncb2 (YDR397C) 45 1
Yol092w (YOL092W) 70 1
Sth1 (YIL126W) 70 2
Ygr043c (YGR043C) 138.4 4
Dsl1 (YNL258C) 72 1 X * 
Pho86 (YJL117W) 71 1 *
Yjr003c (YJR003C) 70.5 2 X X
Lcb1 (YMR296C) 176.5 2 174.7 3 X
Ydr514c (YDR514C) 67 1 * *
Tma19 (YKL056C) 67 1
Yjl062w-a (YJL062W-A) 68 1 X
Ygr110w (YGR110W) 68 1 * * * *
Ypl103c (YPL103C) 68 2 X X * * * 
Rpl4a (YBR031W) 96.7 2 138.6 2 X X * 
Mnn5 (YJL186W) 57.5 1 * 
Spc3 (YLR066W) 57 1 * * 
Fsh3 (YOR280C) 56 1 *
Vph2 (YKL119C) 58 1
Hir1 (YBL008W) 58 1
Rxt3 (YDL076C) 56 1 * 
Ycl045c (YCL045C) 56 2
Ssa1 (YAL005C) 235.2 7 X X
Sur7 (YML052W) 61.5 3 X X
Sec66 (YBR171W) 57 2
Rlf2 (YPR018W) 57 2
Mdm35 (YKL053C-A) 62.5 2 *
Trx1 (YLR043C) 62.5 2
Nic96 (YFR002W) 62 1 *
Yhr097c (YHR097C) 63.7 4
Cdc42 (YLR229C) 57 2
Ynk1 (YKL067W) 63 2 X
Ygr266w (YGR266W) 110.3 2 186 1 X X X
Pdr16 (YNL231C) 60 1
Lys20 (YDL182W) 60 3 X X
Tpo3 (YPR156C) 90.7 2 96 1
Asi1 (YMR119W) 57 1
Kin1 (YDR122W) 84 1
Taf4 (YMR005W) 61 1
Yol053w (YOL053W) 83.8 2 X *
Om14 (YBR230C) 726.8 9 X X X X X
Q0297 (Q0297) 42 1
Yos1 (YER074W-A) 85 1
Clu1 (YMR012W) 85 1
Scp160 (YJL080C) 81.3 3
Rer2 (YBR002C) 81 1 *
Ssz1 (YHR064C) 51 1 * * 
Rot1 (YMR200W) 82 1 * * 
Yhr003c (YHR003C) 276.2 3 X X X * *
Ypt31 (YER031C) 81.8 2 X *
Mmr1 (YLR190W) 92 1 X X X X
Mtg1 (YMR097C) 92 1 X * X
Iml2 (YJL082W) 92 2 X X X
Hop1 (YIL072W) 43 2   
Yhr100c (YHR100C) 94.5 2 X
Nip1 (YMR309C) 94 1
Snf7 (YLR025W) 114.7 2
Csr2 (YPR030W) 88 2
Mob1 (YIL106W) 68 1 * 
Sec22 (YLR268W) 91 2
Pbn1 (YCL052C) 90 1
Tgl4 (YKR089C) 89.5 1 X
Ykt6 (YKL196C) 75.5 2 X X
Dip5 (YPL265W) 75.2 3 X
Gpx2 (YBR244W) 75 1
Kre6 (YPR159W) 76.5 2 * X
Rxt2 (YBR095C) 76 1
Nop58 (YOR310C) 55 1
Sna2 (YDR525W-A) 73 1
Dpp1 (YDR284C) 64.5 1 * 
Yol114c (YOL114C) 72 1 * 
Ylh47 (YPR125W) 234.5 2 402.7 11 X X X * * * *
Rki1 (YOR095C) 74.3 2 * 
Rpl40a (YIL148W) 70 1 144 1
Yer087w (YER087W) 183 2 559.9 8 X X * * * 
Sec1 (YDR164C) 79.7 2
Yfr018c (YFR018C) 79.5 1
Ctr3 (YLR411W) 76 1
Rax1 (YOR301W) 80 1
Rpl26a (YLR344W) 80 1
Rpc10 (YHR143W-A) 78 1
Ast2 (YER101C) 78 1
Sfk1 (YKL051W) 77 1
Rps19b (YNL302C) 79 2 *
Rpl7a (YGL076C) 85 1 X X * *
Pus6 (YGR169C) 79 2 * X
Taf9 (YMR236W) 209.5 1 128.3 3 * *
Srm1 (YGL097W) 196.7 5 * 
Ole1 (YGL055W) 48 1 268 4 X X * *
Ygl080w (YGL080W) 48 1 107.3 2 X X * *
Tbf1 (YPL128C) 48 1
Ykl151c (YKL151C) 48 1
Ygr026w (YGR026W) 48 1 X *
Sap30 (YMR263W) 47 1
Avl9 (YLR114C) 43 2
Nop1 (YDL014W) 47 1 X *
Rps9b (YBR189W) 58 1 81 2 * *
Ygr130c (YGR130C) 48 1 40 2 X *
Moh1 (YBL049W) 47 1
Vps34 (YLR240W) 45 2    *
Rfc1 (YOR217W) 50 1 89 1
Rpp2b (YDR382W) 106 1 X
Pmc1 (YGL006W) 51 1 51 2
Yjr111c (YJR111C) 50 1 *
Far8 (YMR029C) 50 1 *
Yjl171c (YJL171C) 49 1 X X X * 
Rps3 (YNL178W) 154 1 236 3 X *
Rpl2a (YFR031C-A) 48 1 * * 
Rps28b (YLR264W) 50 1 51 1 * * *
Ymr293c (YMR293C) 173.6 3 X X X
Cdc48 (YDL126C) 50 1 44 1 X
Erg1 (YGR175C) 47 1
Alg1 (YBR110W) 44 1 *
Erj5 (YFR041C) 44 1 69.5 1 *
Hmo1 (YDR174W) 334.6 3 134.5 2 X
Pex31 (YGR004W) 44 1 *
Nup170 (YBL079W) 219.8 2 160.4 3 X * 
Dpl1 (YDR294C) 44 1 X *
Sip4 (YJL089W) 43 1 *
Yhr198c (YHR198C) 43 1 379.2 6 X X X X X * 
Swi1 (YPL016W) 43 1 54 1
Trz1 (YKR079C) 199.3 3
Spt10 (YJL127C) 43 1
Dst1 (YGL043W) 97 1
Ste24 (YJR117W) 79 1 X X * 
Sec18 (YBR080C) 45 1 *
Ubx2 (YML013W) 45 1 X
Chs1 (YNL192W) 47 1
Fit2 (YOR382W) 46 1 *
Snf12 (YNR023W) 46 1
Hxt5 (YHR096C) 260.9 4 187.8 4
Spt16 (YGL207W) 45 1 40 1
Ape3 (YBR286W) 44 1 * 
Ydr020c (YDR020C) 45 1 *
Zta1 (YBR046C) 45 1 * 
Rsp5 (YER125W) 45 1 197.8 4 X X
Srp54 (YPR088C) 57 1
Mgs1 (YNL218W) 57 1 * 
Ptr2 (YKR093W) 96 2 232 3
Yor390w (YOR390W) 59 1 129 1 * 
Ypl279c (YPL279C) 59 1 129 1 * 
Erg11 (YHR007C) 185.8 5 X X *
Mcm3 (YEL032W) 51 1
Erg25 (YGR060W) 47 1 * *
Pab1 (YER165W) 206.6 5
Fcf2 (YLR051C) 41 1
Rpl27a (YHR010W) 57 1 68.5 2 X * * 
Yrr1 (YOR162C) 57 1 41 2 *
Cdc10 (YCR002C) 60 1 156.8 3 * 
Vps13 (YLL040C) 60 1 56.8 6 X X
Spt8 (YLR055C) 59 1
Pbi2 (YNL015W) 61 1 154.3 3
Hor2 (YER062C) 61 1 50 2
Plb1 (YMR008C) 60 1 X
Cta1 (YDR256C) 186.7 2 106 1
Ste18 (YJR086W) 127 1
Orm1 (YGR038W) 59 1 201.5 1 * 
Brx1 (YOL077C) 45 1 *
Rps22b (YLR367W) 59 1 *
Dal81 (YIR023W) 59 1
Nup57 (YGR119C) 55 1
Scw4 (YGR279C) 52 1 125.3 2
Orc1 (YML065W) 52 1 44.5 1
Acc1 (YNR016C) 52 1 40 2 X X
Rpl20a (YMR242C) 96.3 2 74 1 X X * *
Rho1 (YPR165W) 114.7 2 385.1 6 X X X
Rpb8 (YOR224C) 52 1
Nug1 (YER006W) 51 1 * 
Ymr194c-b (YMR194C-B) 51 1
Ybl095w (YBL095W) 114.5 2 X X * 
Myo3 (YKL129C) 52 1 40 2
Act1 (YFL039C) 88.5 1 101.8 6 X X
Rps10a (YOR293W) 51.5 1
Lhs1 (YKL073W) 54 1 171.7 2
Ssb1 (YDL229W) 344.5 8 457.1 9 X X *
Lag1 (YHL003C) 53 1
Pos5 (YPL188W) 61.5 2 X X * * X
Rsc9 (YML127W) 55 1
Rnq1 (YCL028W) 54 1
Msc7 (YHR039C) 53 1 57 2 X
Fpr3 (YML074C) 52 1
Glc7 (YER133W) 60 1 *
Mcm1 (YMR043W) 53 1
Mgr2 (YPL098C) 53 1 100.7 1 * 
Hsf1 (YGL073W) 71.5 1 40 2 X X
Bna4 (YBL098W) 101 3 155.2 4 X X X X * *
Sfh5 (YJL145W) 137.5 2 * 
Vac8 (YEL013W) 62 2 X
Ino80 (YGL150C) 136.3 1 112.3 3
Pho23 (YNL097C) 104.5 1
Htz1 (YOL012C) 117 1
Yor271c (YOR271C) 240.1 4 166.8 3 X X * X
Fpr1 (YNL135C) 140 2 84 1 X
Slm1 (YIL105C) 166.5 1 X X
Pex19 (YDL065C) 71 1
Rhr2 (YIL053W) 61 1 X * * 
Rfc3 (YNL290W) 109 1 * *
Rpl13a (YDL082W) 116 2 206.3 3 X * * 
Van1 (YML115C) 88 2 * 
Ada2 (YDR448W) 58 1
Pep4 (YPL154C) 148.3 2 X X
Rrp14 (YKL082C) 41 1
Sec61 (YLR378C) 66 1 X *
Ydr348c (YDR348C) 62 1 * 
Ulp1 (YPL020C) 78.5 1 110 1
Yjl193w (YJL193W) 70 1 * 
Rpp1b (YDL130W) 88 1 X X
Fat1 (YBR041W) 40 1 * *
Yif1 (YNL263C) 41 1 116 1
Stl1 (YDR536W) 106.5 2 X * 
Rvb2 (YPL235W) 65.5 2 184.3 4
Ygr031w (YGR031W) 132 2 195.2 3 X * * * *
Pmt2 (YAL023C) 82.5 1 341 4 X
Put1 (YLR142W) 181.1 5 263.7 5 X X * * * * X
Rli1 (YDR091C) 119 2
Ngl1 (YOL042W) 293.2 3 X * * 
Rsm28 (YDR494W) 291.1 7 444.5 5 X X * X
Irs4 (YKR019C) 40 1 X X    *
Pmt4 (YJR143C) 75.5 1 91.3 4 X
Rps19a (YOL121C) 79 2 *
Tna1 (YGR260W) 46.5 1 X X   
Cdc12 (YHR107C) 111.8 3 60.7 3
Arc19 (YKL013C) 42 1 * 
Yjl131c (YJL131C) 239.5 3 X * *
Rps8a (YBL072C) 79.5 2 63 1 X *
Rpl17b (YJL177W) 94.3 2 X X * 
Ndc1 (YML031W) 59 1 64 2
Sec17 (YBL050W) 213.5 2 246.5 3 *
Fet4 (YMR319C) 40 1
Rpl31a (YDL075W) 49 1 *
Rps22a (YJL190C) 59 1 *
Snl1 (YIL016W) 45 1 X X *
Rad5 (YLR032W) 53 1
Vps66 (YPR139C) 41 1 * *
Yhr138c (YHR138C) 43 1
Arf1 (YDL192W) 90 1 68 1 X * 
Vtc2 (YFL004W) 77 1 * *
Mid2 (YLR332W) 69.5 1 *
Rrf1 (YHR038W) 41 1 364.2 4 X X X X * * * X
Erg9 (YHR190W) 41 1 247.2 4 X X
Yet3 (YDL072C) 41 1 195.7 6 * 
Bgl2 (YGR282C) 58 2
Ymr209c (YMR209C) 101.3 2 *
Ygr093w (YGR093W) 66 1
Var1 (Q0140) 127.6 2 88.5 1 X X X X * X
Sbh1 (YER087C-B) 42 1 * *
Snz3 (YFL059W) 52 1
Not3 (YIL038C) 45 1
Car1 (YPL111W) 111 1 * 
Rog1 (YGL144C) 42 1
Ecm4 (YKR076W) 248 2 * * 
Chs6 (YJL099W) 42 1
Sum1 (YDR310C) 42 1 X
Lsm4 (YER112W) 41 1
Rgr1 (YLR071C) 41 1
Pol2 (YNL262W) 56 1 X
Bbc1 (YJL020C) 42 1 40 1 X
Ydl177c (YDL177C) 121.5 1 43 1
Kre2 (YDR483W) 41 1 * 
Alo1 (YML086C) 400.5 8 342.4 7 X X X X X * X
Stt3 (YGL022W) 162 2 122.5 3 *
Ykl027w (YKL027W) 163.8 3 343 8 X X X X X * *
Vps1 (YKR001C) 63 1 331.1 9 X
Snz2 (YNL333W) 52 1
Mdh3 (YDL078C) 294.5 5 144 4 * *
Alg2 (YGL065C) 51 1 164 2
Utr2 (YEL040W) 106 2 *
Ybl029c-a (YBL029C-A) 106.3 1
Ibd2 (YNL164C) 51 1
Dps1 (YLL018C) 57 1 X
Mck1 (YNL307C) 58 2
Syp1 (YCR030C) 158.3 2
Put4 (YOR348C) 72 1
Ynr034w-a (YNR034W- 119 1
Rsc4 (YKR008W) 46 1
Ioc3 (YFR013W) 55 1
Smt3 (YDR510W) 81 1
Rps26b (YER131W) 66 1
Rap1 (YNL216W) 205.8 3 374.3 4
Hmg1 (YML075C) 52 1 73.5 2 * * 
Ume6 (YDR207C) 261.2 2
Rho2 (YNL090W) 55.5 1
Taf5 (YBR198C) 543.2 5
Rpl25 (YOL127W) 198.5 2 321.5 4 * * 
Get1 (YGL020C) 122 1 171.3 2 X
Tcb1 (YOR086C) 146.8 4 569.3 11 X X X *
Nif3 (YGL221C) 121 2 132.5 2 X
Hsp104 (YLL026W) 52 1 * 
Oct1 (YKL134C) 126.4 2 139.3 3 X * * X
Yet1 (YKL065C) 122.7 3 116 1
Yju3 (YKL094W) 116.3 3 136 1 X X
Gea2 (YEL022W) 46 1
Rpl16a (YIL133C) 45 2 X   
Ady2 (YCR010C) 129.7 2 305.4 4 X X
Ydr061w (YDR061W) 146.4 4 124 3 X X X * 
Rfs1 (YBR052C) 116.3 1 X *
Cpr5 (YDR304C) 136.3 1 90 2 X
Sin3 (YOL004W) 135 1
Cbf1 (YJR060W) 132 1 X X
Sso2 (YMR183C) 138.3 2 143.3 3 X
Yil108w (YIL108W) 138 1 84 3
Ras1 (YOR101W) 137.7 2
Mgr1 (YCL044C) 120 2 133.6 4 X X X * X
Bmh1 (YER177W) 128.3 2 68.5 2 X * 
Sar1 (YPL218W) 128 2 92 1 X X
Ncp1 (YHR042W) 131.5 1 460.5 5 X X X * 
Rps20 (YHL015W) 130.7 2 71 1
Nsp1 (YJL041W) 130 1 191.3 2 *
Ste12 (YHR084W) 77 1
Mcm4 (YPR019W) 43 1 42 1 *
Rpl19b (YBL027W) 98 2 233 2 X X * * 
Snq2 (YDR011W) 94.5 2 X X X
Scj1 (YMR214W) 104.5 1 60 1 * 
Ydr381c-a (YDR381C-A) 149.8 2 40 2 X X
Mdh2 (YOL126C) 44 1 * 
Rpl27b (YDR471W) 57 1 68.5 2 X * * 
Rpl4b (YDR012W) 96.7 2 138.6 2 X X * *
Rga2 (YDR379W) 96.5 1
Hyr1 (YIR037W) 98 3 113.5 1
Enb1 (YOL158C) 43 1
Gas3 (YMR215W) 97 1 89 2 *
Str3 (YGL184C) 113 2
Nhp6a (YPR052C) 52.8 3 X   
Hht1 (YBR010W) 111 1 X * 
Ybr255c-a (YBR255C-A) 230 3 * *
Smf3 (YLR034C) 53 1 63 1
Prd1 (YCL057W) 113.7 2 176.7 2 X X X X * * X
Cho2 (YGR157W) 106.5 1 260 6 X
Yil087c (YIL087C) 157.3 1 X X
Arf2 (YDL137W) 90 1 68 1 X * *
Hht2 (YNL031C) 111 1 X * 
Prp6 (YBR055C) 40 3 *   
Crp1 (YHR146W) 109 1 53 1
Cpr1 (YDR155C) 179 4 532 4 X X X
Gnp1 (YDR508C) 49 1 X X * *
Hom6 (YJR139C) 68 3 X
Rbg1 (YAL036C) 80 2 * 
Tos1 (YBR162C) 151.7 2 * *
Nup145 (YGL092W) 179.7 2 X * *
Ynr021w (YNR021W) 164 3 190.7 3 X * *
Ydr056c (YDR056C) 213 2
Yml050w (YML050W) 501.9 3 * * *
Rps27b (YHR021C) 62 1
Hho1 (YPL127C) 174.4 2 48 1
Ded1 (YOR204W) 80 1 X *
Rps6a (YPL090C) 197.2 3 156.8 2 X X *
Cwh43 (YCR017C) 78 1 50 1 * 
Stm1 (YLR150W) 142.3 2 102.7 3
Sec20 (YDR498C) 40 1
Faa4 (YMR246W) 201.8 3 118 2 X
Rps6b (YBR181C) 197.2 3 156.8 2 X X *
Mbf1 (YOR298C-A) 59 1 X X
Ypt1 (YFL038C) 184 2 160 3 X X X
Ygr235c (YGR235C) 183.3 5 365.6 9 X X X *
Nca2 (YPR155C) 195.8 3 536.3 8 X X X X *
Gsf2 (YML048W) 193.8 4 130 4 X *
Fun14 (YAL008W) 188.7 1 193 2 X X X X * * 
Erp2 (YAL007C) 161.3 2 116.3 2
She9 (YDR393W) 145.3 2 466.1 11 X * * * X
Hta1 (YDR225W) 493.7 6 128.3 2 X X
Fmp46 (YKR049C) 143.3 2 369.1 7 X X X * 
Erp4 (YOR016C) 104 1 * 
Snz1 (YMR096W) 52 1
Mls1 (YNL117W) 118.7 3 40 1
Eft2 (YDR385W) 139 3 229.8 9 X
Yro2 (YBR054W) 138.7 2 40 1 X X X
Hsp82 (YPL240C) 171.3 2 X
Top1 (YOL006C) 196.5 3 * 
Hsp26 (YBR072W) 140.3 2 40 1
Eft1 (YOR133W) 139 3 229.8 9 X X
Isw1 (YBR245C) 155.3 3 132.5 3
Arp4 (YJL081C) 154 2
Taf6 (YGL112C) 49 1 129.7 2
Asg1 (YIL130W) 159 3 * 
Hfd1 (YMR110C) 158.3 5 237 4 X X X X X * X
Rpl8b (YLL045C) 93.7 1 69 1 X
Yer004w (YER004W) 151.4 3 138.8 4 X X X X X X *
Ykr070w (YKR070W) 103.5 2 329.4 6 X X * X
Ypl107w (YPL107W) 148.5 1 239.5 1 * * 
Mcm6 (YGL201C) 154 2 108 2
Wbp1 (YEL002C) 153.4 3 X X
Assembly4 (YDL088C) 181 2
Nup53 (YMR153W) 214.5 1
Rpl40b (YKR094C) 70 1 144 1 X X
Ubi4 (YLL039C) 70 1 144 1
Rfc4 (YOL094C) 73 1 *
Rpl18a (YOL120C) 71 1 41 1 X * 
Rpl18b (YNL301C) 71 1 41 1 * 
Dig1 (YPL049C) 70 1
Faa2 (YER015W) 69 1 X X *
Rps21a (YKR057W) 68 1 *
Hch1 (YNL281W) 68 1
Rps31 (YLR167W) 70 1 144 1 X
Ycp4 (YCR004C) 69.5 1 462 5 X X X *
Ent4 (YLL038C) 120.5 1 * 
Rpl3 (YOR063W) 74.5 1 96 2 X X * 
Rpl15b (YMR121C) 73.5 1
Ssh1 (YBR283C) 60 1 X
Cox19 (YLL018C-A) 76 1 X
Gcn1 (YGL195W) 66.7 3 X X
Ygl231c (YGL231C) 75 1
Rrp5 (YMR229C) 72.5 1 51 2
Aro10 (YDR380W) 72 2 * 
Gpm1 (YKL152C) 71 1 171.4 5 X X X
Rpl15a (YLR029C) 73.5 1 40 1 *
Rpl30 (YGL030W) 73 1 * *
Rpt6 (YGL048C) 73 1 *
Rho5 (YNL180C) 87 1
Yor020w-a (YOR020W- 278.9 2 144 1 X
Pex30 (YLR324W) 63 1 273.6 4 *
Ynr040w (YNR040W) 63 1 109.3 2 X X *
Vhs3 (YOR054C) 64 1 *
Nsg2 (YNL156C) 64 1
Rps7a (YOR096W) 64 1 61.5 2 X X *
Ygl118c (YGL118C) 62 2
Epl1 (YFL024C) 62 2
Arp2 (YDL029W) 60 1 *
Cue1 (YMR264W) 63 1 75.5 3 X X
Ybl059c-a (YBL059C-A) 176 2 209.1 3 * 
Pom34 (YLR018C) 53 1 *
Ycl033c (YCL033C) 57 1 * * * 
Rpl12a (YEL054C) 102.7 3 X *
Tyw1 (YPL207W) 66 1 66 2 * 
Rps21b (YJL136C) 68 1
Yhr199c (YHR199C) 68 2 95 2 X X X * * 
Pat1 (YCR077C) 67 1
Irr1 (YIL026C) 64.5 1
Ydr476c (YDR476C) 64.5 1
Ycr051w (YCR051W) 54 1
Ykl133c (YKL133C) 66 1 40 2 * *
Hoc1 (YJR075W) 40 1 * *
Pob3 (YML069W) 65 1
Rrp12 (YPL012W) 48 1
Ypl099c (YPL099C) 132 1 X X X * * * *
Rtn1 (YDR233C) 258.2 2 158 6 X X X * 
Ylr225c (YLR225C) 61.5 1
Erv29 (YGR284C) 44 1 68 1 X
Rpl16b (YNL069C) 89.5 2
Lcb2 (YDR062W) 83.5 2 59 1
Ssm4 (YIL030C) 83 1
Grx1 (YCL035C) 104.5 1
Ngg1 (YDR176W) 85 1 * 
Stu2 (YLR045C) 59 1
Coa1 (YIL157C) 83.5 2 152.6 8 X X X X X X * * * * X
Pox1 (YGL205W) 94.5 2 X * *
Ylr356w (YLR356W) 152.6 1 80 1
Rpl17a (YKL180W) 94.3 2 X * 
Ymc1 (YPR058W) 146.7 1 49.5 2 X X X X * X
Ast1 (YBL069W) 63 1
Isd11 (YER048W-A) 95.8 3 102.7 2 X X X * *
Fps1 (YLL043W) 93 1
Gal11 (YOL051W) 92.5 1
Gis2 (YNL255C) 91.3 2
Hpc2 (YBR215W) 94 1 *
Rpl8a (YHL033C) 93.7 1 69 1 X * 
Sec31 (YDL195W) 91.7 2 *
Alg9 (YNL219C) 82 1
Fre1 (YLR214W) 78.5 1 49 1 * 
Gpt2 (YKR067W) 78 2 310.9 6 *
Rps18b (YML026C) 78 1 88 2 X X *
Sbh2 (YER019C-A) 79 1 * *
Rpl23a (YBL087C) 79 1 129 1 X X *
Sec9 (YGR009C) 110 1
Zrc1 (YMR243C) 77 1
Htb2 (YBL002W) 115.8 2 93 3 X X
Mpd2 (YOL088C) 77 1 *
Taf2 (YCR042C) 48 1 * 
Pus9 (YDL036C) 129.2 3 * 
Fre7 (YOL152W) 77.5 2
Ypr098c (YPR098C) 81 2 46.7 1 X X * *
Reb1 (YBR049C) 80.5 2 *
Afg1 (YEL052W) 80.5 2 366.8 7 X X X X * * 
Adh2 (YMR303C) 81.5 2 155.5 4 X X
Icl1 (YER065C) 81 1
Mic17 (YMR002W) 369.2 8 * * *
Rps8b (YER102W) 79.5 2 63 1 X
Bud14 (YAR014C) 45 1
Dfm1 (YDR411C) 79 1 * *
Yef3 (YLR249W) 165 1 270.6 3 X
Sok2 (YMR016C) 80 1
Rsc58 (YLR033W) 48 1 55 1





























nazwy na podstawie bazy SGD z 12/12/2007
ORF name Common Protein Name
YLL018C  Asprs Dps1 
YKL055C  Oar1 
YDL164C  Mms8 Cdc9 
YCL004W  Pel1 Pgs1 Ycl003w 
YKL114C  Apn1 
YPR163C  Rbl3 Tif3 Stm1 
YNL066W  Scw3 Sun4 
YGR046W  Ygr046w 
YHL038C  Cbp2 
YPR181C  Sec23 
YBR029C  Cdg1 Cds1 
YKR087C  Oma1 
YOR147W  Mdm32 
YMR166C  Ymr166c 
YHR086W  Mre2 Nam8 Mud15 
YHR011W  Dia4 
YNR020C  Ynr020c 
YNL081C  Sws2 
YDL107W  Mss2 
YHR116W  Cox23 
YPL060W  Lpe10 
YGR257C  Mtm1 
YGR169C  Pus6 
YNL292W  Pus4 
YPL005W  Aep3 
YNL328C  Mdj2 
YDL045W-A  Mrp10 
YGL236C  Ips1 Mto1 
YHR168W  Mtg2 
YEL059C-A  Som1 
YLL018C-A  Cox19 
YPR159W  Cwh48 Kre6 
YOR226C  Nua2 Isu2 
YLR289W  Guf1
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No. description
n
u
m
b
er o
f p
ro
tein
s 
p
red
icted
P
flieger et al. [22]
79 Components of the large subunit of mitochondrial ribosomes-MRPL 48 44 14
99 Components of the small subunit of mitochondrial ribosomes-MRPS 38 33 3
155 Respiratory Chain Complex-V 18 16 12
16 Tim23/Tim22 complex 16 16 2
58 Vacuolar acidification 16 3 0
62 Translation regulator activity 15 11 2
1 Respiratory Chain Complex-IV 14 11 10
20 Iron-sulfur cluster assembly 13 11 2
37 Pyruvate/α-ketoglutarate dehydrogenase 13 11 8
95 NAD metabolism/TCA cycle 13 13 9
132 Cytoplasmic ribosome 13 8 1
61 RNA splicing 12 8 0
7 Ubiquinone metabolism 11 8 0
49 TOM complex 11 11 3
98 tRNA/rRNA processing 11 1 0
8 Branched chain amino acid biosynthesis 10 9 6
15 Matrix protein import 10 9 6
46 Folate and glycine metabolism 10 6 2
103 Alcohol/aldehyde dehydrogenase 10 7 3
156 Respiratory Chain Complex-III 10 9 6
6 Mitochondrial organisation and morphology 9 7 1
147 Respiratory Chain Complex-II 9 7 7
22 Secretory pathway 8 4 0
41 DNA replication 8 3 0
45 cytoplasmic lipid metabolism 8 3 1
48 Glycerol metabolism 8 6 1
66 Amino acid metabolism 8 4 0
35 Response to DNA damage 7 3 1
80 tRNA aminoacylation 7 5 0
9 Respiratory Chain Complex assembly 1 6 5 0
27 Unknown module 1 6 4 0
31 Glutamate biosynthesis 6 3 2
64 Fusion/fission 6 5 1
Modules according to Perocchi at al. [36] Other MS based proteomic studies
th
is stu
d
y F
T
IC
R
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149 Isocitrate metabolism 6 5 4
4 Cell growth regulation 5 3 0
10 Mitochondrial protein targeting 5 5 0
12 Fatty acid biosynthesis 5 2 0
17 Unknown module 2 5 2 0
24 Glutamine family metabolism 5 1 0
28 Respiratory Chain Complex assembly 2 5 5 1
30 Mitochondrial/cytoplasmic lipid metabolism 5 5 2
51 Arginine biosynthesis 5 3 0
54 Cell wall organisation and biogenesis 5 4 0
69 Respiratory Chain Complex-IV assembly 5 3 0
105 Mismatch repair 5 0 0
115 Transport 5 5 0
O
hlm
eier et al. [23]
P
rokisch et al. [24]
Sickm
ann at al. [25]
Z
ahedi et al. [26]
R
einders et al. [27]
P
rokisch at al.N
. crassa
6 24 39 1 42 7
6 22 27 2 32 4
9 16 17 4 18 14
4 7 13 3 16 5
2 1 0 0 0 0
1 2 14 0 14 1
6 13 14 0 13 10
5 8 9 0 10 0
11 10 12 3 12 8
7 13 13 5 13 8
0 10 2 0 2 4
2 2 8 0 8 2
5 5 7 0 8 1
4 8 10 10 11 6
0 1 1 0 1 0
7 9 8 2 8 5
7 9 9 3 9 2
3 6 8 0 8 1
6 5 7 1 7 3
5 8 10 2 10 8
3 3 5 3 6 2
5 7 8 2 8 9
1 2 1 0 1 0
2 1 3 0 4 1
1 2 4 1 4 0
1 1 4 1 4 1
3 2 4 0 5 0
1 3 4 0 4 0
1 2 4 0 4 2
1 2 3 0 4 1
0 0 1 0 2 0
3 3 6 0 6 0
1 3 5 5 6 5
Other MS based proteomic studies
5 6 6 0 6 5
0 1 2 0 2 0
1 2 4 1 4 4
0 0 3 0 4 0
0 0 2 0 2 0
1 2 2 0 2 2
0 2 4 0 4 0
2 5 5 1 5 2
3 3 3 0 3 1
0 3 3 0 3 0
1 2 5 0 5 2
0 0 2 0 2 0
0 1 3 0 4 2
Sheet1
module 
No.
predicted mitochondrial 
complex
PSI+/p
si-
P
PSI+/p
si- 
P
mean 
PSI+/psi-
Cox4 (YGL187C) 0.68 0.02  N/A N/A 0.68
Cox5a (YNL052W) 1.67 0.05  N/A N/A 1.67
Cox2 (Q0250) 0.28 0.00 0.37 0.00 0.32
Cox6 (YHR051W) 0.36 0.01  N/A N/A 0.36
Cox13 (YGL191W) 1.66 0.12 1.43 0.02 1.54
5 Odc2 (YOR222W) 0.20 0.03  N/A N/A 0.20
Phb2 (YGR231C) 0.75 0.11 0.67 0.00 0.71
Phb1 (YGR132C) 0.53 0.06 0.61 0.00 0.57
Ilv2 (YMR108W)  N/A  N/A 1.28 0.00 1.28
Ilv6 (YCL009C)  N/A  N/A 1.35 0.00 1.35
Ilv3 (YJR016C)  N/A  N/A 1.22 0.01 1.22
Ilv5 (YLR355C) 0.67 0.00 0.74 0.00 0.70
Leu4 (YNL104C) 1.31 0.04 1.32 0.00 1.31
Bat1 (YHR208W) 1.43 0.11 1.43 0.00 1.43
9
Respiratory Chain 
Complex assembly 1 Atp11 (YNL315C) 0.41 0.09  N/A N/A 0.41
Abf2 (YMR072W)  N/A  N/A 1.35 0.00 1.35
Mmf1 (YIL051C)  N/A  N/A 1.51 0.00 1.51
Ssc1 (YJR045C) 0.75 0.00 0.74 0.00 0.74
Hsp10 (YOR020C)  N/A  N/A 1.33 0.00 1.33
Hsp78 (YDR258C) 2.16 0.00 1.92 0.00 2.04
Hsp60 (YLR259C)  N/A  N/A 1.13 0.00 1.13
Ecm10 (YEL030W)  N/A  N/A 0.71 0.00 0.71
16  Tim23/Tim22 complex Tim44 (YIL022W) 1.29 0.15  N/A N/A 1.29
19 Lys12 (YIL094C)  N/A  N/A 1.52 0.00 1.52
21 Tdh3 (YGR192C) 0.67 0.05 2.00 0.00 1.16 1
22  Secretory pathway Kar2 (YJL034W) 1.42 0.07 2.13 0.00 1.74
Cbp3 (YPL215W) 2.52 0.09  N/A N/A 2.52
Cbp4 (YGR174C) 1.77 0.14  N/A N/A 1.77
29 Lsp1 (YPL004C) 2.56 0.01 3.70 0.00 3.08
Psd1 (YNL169C) 0.17 0.01  N/A N/A 0.17
Yhm2 (YMR241W)  N/A  N/A 0.67 0.01 0.67
31 Glutamate biosynthesis Put2 (YHR037W)  N/A  N/A 1.61 0.00 1.61
35
 Response to DNA 
damage Mgm101 (YJR144W) 1.39 0.15  N/A N/A 1.39
Pdb1 (YBR221C) 1.39 0.11  N/A  N/A 1.39
Pdx1 (YGR193C) 1.94 0.06  N/A N/A 1.94
WPES
protein name (ORF)
1
Respiratory Chain 
Complex-IV
6
Mitochondrial organisation 
and morphology
Modules according to Perocchi at 
al. [36] FTICR
15  Matrix protein import
25
8
Branched chain amino 
acid biosynthesis
13
30
Mitochondrial/cytoplasmic 
lipid metabolism
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Sheet1
Lat1 (YNL071W)  N/A  N/A 1.29 0.00 1.29
Prx1 (YBL064C) 3.34 0.00 1.64 0.00 2.34
Kgd2 (YDR148C) 1.27 0.14  N/A N/A 1.27
Kgd1 (YIL125W) 0.76 0.02 0.90 0.00 0.83
Pda1 (YER178W)  N/A  N/A 1.34 0.00 1.34
Adk2 (YER170W) 0.48 0.05  N/A N/A 0.48
Mam33 (YIL070C) 0.25 0.00 0.76 0.00 0.44
43 Cpr3 (YML078W) 0.73 0.14 0.65 0.00 0.69
45
Cytoplasmic lipid 
metabolism Pil1 (YGR086C) 2.40 0.02 4.00 0.00 3.10
Gcv3 (YAL044C)  N/A  N/A 1.54 0.02 1.54
Gcv1 (YDR019C) 1.29 0.11 1.96 0.00 1.59
Tom22 (YNL131W)  N/A  N/A 1.75 0.00 1.75
Tom20 (YGR082W) 0.53 0.08  N/A N/A 0.53
Tom40 (YMR203W) 0.71 0.11 0.75 0.00 0.73
54
Cell wall organisation and 
biogenesis Gas1 (YMR307W)  N/A  N/A 2.17 0.00 2.17
58  Vacuolar acidification Tfp1 (YDL185W) 3.97 0.01 10.00 0.00 6.30
62
Translation regulator 
activity Pet54 (YGR222W) 4.46 0.11  N/A N/A 4.46
63 Odc1 (YPL134C) 0.29 0.01 0.60 0.00 0.42
Ilv1 (YER086W) 1.42 0.11 1.72 0.01 1.56
Cha1 (YCL064C) 1.84 0.12 1.61 0.01 1.72
67 Tuf1 (YOR187W) 0.73 0.09  N/A  N/A 0.73
70 Mir1 (YJR077C) 0.74 0.02  N/A  N/A 0.74
71 Ccp1 (YKR066C) 1.80 0.11  N/A N/A 1.80
72 Nuc1 (YJL208C) 0.27 0.07  N/A N/A 0.27
Erg6 (YML008C)  N/A  N/A 1.49 0.01 1.49
Eht1 (YBR177C) 10.67 0.10  N/A N/A 10.67
Mrpl6 (YHR147C) 2.87 0.11  N/A N/A 2.87
Rml2 (YEL050C) 0.40 0.14  N/A N/A 0.40
Mrpl10 (YNL284C) 0.31 0.10  N/A N/A 0.31
Sod1 (YJR104C)  N/A  N/A 0.57 0.01 0.57
Sod2 (YHR008C)  N/A  N/A 1.20 0.00 1.20
85 Ecm33 (YBR078W)  N/A  N/A 2.28 0.00 2.28
93 Por1 (YNL055C) 0.73 0.01 0.94 0.00 0.83
Dld1 (YDL174C) 0.64 0.04  N/A  N/A 0.64
Ypr004c (YPR004C) 0.50 0.05  N/A  N/A 0.50
Nde2 (YDL085W) 1.46 0.11  N/A  N/A 1.46
Cit1 (YNR001C)  N/A  N/A 0.92 0.00 0.92
Ndi1 (YML120C) 0.79 0.10 0.83 0.00 0.81
Mdh1 (YKL085W) 0.71 0.02  N/A  N/A 0.71
41  DNA replication
46
Folate and glycine 
metabolism
37
Pyruvate/α-ketoglutarate 
dehydrogenase 
75
79
Components of the large 
subunit of mitochondrial 
ribosomes-MRPL
49  TOM complex
66 Amino acid metabolism
81
95
NAD metabolism/TCA 
cycle
Page 2
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Nde1 (YMR145C) 1.64 0.00 1.52 0.00 1.58
Yor356w (YOR356W) 2.51 0.06  N/A N/A 2.51
Cit3 (YPR001W) 6.35 0.03  N/A N/A 6.35
96 Mdl2 (YPL270W) 1.59 0.11  N/A N/A 1.59
99
Components of the small 
subunit of mitochondrial 
ribosomes-MRPS Mrp13 (YGR084C) 0.30 0.12  N/A N/A 0.30
102 Leu9 (YOR108W) 1.81 0.01 1.69 0.00 1.75
Ald4 (YOR374W) 0.66 0.00 0.85 0.00 0.75
Adh3 (YMR083W)  N/A  N/A 0.79 0.00 0.79
Ach1 (YBL015W) 0.66 0.00 0.70 0.00 0.68
Ald5 (YER073W)  N/A  N/A 0.74 0.01 0.74
104 Sfc1 (YJR095W) 0.57 0.02  N/A  N/A 0.57
Pdh1 (YPR002W) 0.69 0.07  N/A N/A 0.69
Om45 (YIL136W) 1.43 0.01 1.41 0.00 1.42
123 Cat2 (YML042W)  N/A  N/A 0.71 0.01 0.71
128 Grx2 (YDR513W) 1.80 0.09  N/A N/A 1.80
129 Msw1 (YDR268W) 0.35 0.11  N/A N/A 0.35
Pet9 (YBL030C) 0.64 0.05 0.83 0.00 0.73
Aac1 (YMR056C)  N/A  N/A 0.54 0.00 0.54
Aac3 (YBR085W)  N/A  N/A 0.60 0.00 0.60
144 Cyt2 (YKL087C) 0.20 0.03  N/A N/A 0.20
Lsc2 (YGR244C) 1.53 0.01 1.16 0.00 1.33
Sdh2 (YLL041C)  N/A  N/A 0.63 0.00 0.63
Yjl045w (YJL045W)  N/A  N/A 0.76 0.00 0.76
Lsc1 (YOR142W)  N/A  N/A 1.27 0.00 1.27
Sdh1 (YKL148C) 0.61 0.00 0.63 0.00 0.62
Sdh3 (YKL141W)  N/A  N/A 0.59 0.00 0.59
Cbr1 (YIL043C) 1.81 0.11  N/A N/A 1.81
Mcr1 (YKL150W) 0.36 0.00 0.38 0.00 0.37
Idh1 (YNL037C) 0.54 0.02 0.82 0.00 0.67
Aco1 (YLR304C) 0.66 0.00 0.78 0.00 0.72
Idp3 (YNL009W)  N/A  N/A 1.39 0.00 1.39
Idp1 (YDL066W)  N/A  N/A 1.47 0.00 1.47
Idh2 (YOR136W) 0.47 0.00  N/A  N/A 0.47
Atp4 (YPL078C)  N/A  N/A 1.11 0.01 1.11
Atp15 (YPL271W)  N/A  N/A 0.77 0.00 0.77
Atp1 (YBL099W) 0.62 0.00 0.89 0.00 0.74
Atp16 (YDL004W) 0.61 0.04  N/A N/A 0.61
Atp3 (YBR039W) 0.52 0.00 0.87 0.00 0.67
Atp2 (YJR121W) 0.61 0.00 0.83 0.00 0.71
Cyt1 (YOR065W) 0.40 0.01  N/A  N/A 0.40
103
Alcohol/aldehyde 
dehydrogenase
109
148
149 Isocitrate metabolism
134
147
Respiratory Chain 
Complex-II 
155
Respiratory Chain 
Complex-V
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Qcr2 (YPR191W)  N/A  N/A 1.19 0.00 1.19
Qcr10 (YHR001W-A) 0.08 0.01  N/A N/A 0.08
Qcr6 (YFR033C) 0.49 0.09  N/A N/A 0.49
Rip1 (YEL024W)  N/A  N/A 1.32 0.00 1.32
Pma2 (YPL036W)  N/A  N/A 3.28 0.00 3.28
Pma1 (YGL008C) 1.29 0.06 2.94 0.00 1.95
Hxt7 (YDR342C)  N/A  N/A 1.43 0.00 1.43
Hxt6 (YDR343C) 0.52 0.03 1.72 0.00 0.95 1
Alo1 (YML086C) 1.48 0.11  N/A  N/A 1.48
Tdh1 (YJL052W) 1.40 0.10 2.70 0.00 1.94
Sec61 (YLR378C) N/A  N/A 1.96 0.01 1.96
Tef2 (YBR118W) N/A  N/A 3.70 0.00 3.70
Rsm28 (YDR494W) 1.72 0.12  N/A N/A 1.72
Ynl208w (YNL208W) 15.49 0.05  N/A N/A 15.49
Sar1 (YPL218W) 4.44 0.12  N/A N/A 4.44
Hht1 (YBR010W) N/A  N/A 5.56 0.00 5.56
Tef1 (YPR080W) N/A  N/A 3.85 0.00 3.85
Ycp4 (YCR004C) 5.24 0.03 4.17 0.00 4.67
Hht2 (YNL031C) N/A  N/A 5.56 0.00 5.56
Ssa2 (YLL024C) 0.51 0.11 2.70 0.01 1.17 1
Tdh2 (YJR009C) N/A  N/A 2.32 0.00 2.32
Htb1 (YDR224C) N/A  N/A 4.08 0.00 4.08
Hta1 (YDR225W) N/A  N/A 4.17 0.00 4.17
Hhf2 (YNL030W) N/A  N/A 4.78 0.00 4.78
Hho1 (YPL127C) N/A  N/A 3.33 0.00 3.33
Htb2 (YBL002W) N/A  N/A 4.08 0.00 4.08
Yor084w (YOR084W) N/A  N/A 2.97 0.00 2.97
Faa4 (YMR246W) 4.75 0.07  N/A N/A 4.75
Hmo1 (YDR174W) N/A  N/A 2.94 0.00 2.94
Hta2 (YBL003C) N/A  N/A 4.76 0.00 4.76
Ssb1 (YDL229W) N/A  N/A 3.33 0.00 3.33
Hhf1 (YBR009C) N/A  N/A 4.57 0.00 4.57
Pdi1 (YCL043C) N/A  N/A 1.72 0.01 1.72
Idp2 (YLR174W) N/A  N/A 1.33 0.00 1.33
Nce102 (YPR149W) 3.60 0.06  N/A N/A 3.60
Ynr018w (YNR018W) 0.53 0.11  N/A N/A 0.53
Bna4 (YBL098W) 2.98 0.12  N/A N/A 2.98
Put1 (YLR142W) 3.07 0.12  N/A N/A 3.07
Ras2 (YNL098C) 6.30 0.10  N/A N/A 6.30
Pos5 (YPL188W) 3.13 0.07  N/A N/A 3.13
Pck1 (YKR097W) 0.30 0.02  N/A N/A 0.30
Pgk1 (YCR012W) 0.14 0.02  N/A N/A 0.14
  
158
160
156
Respiratory Chain 
Complex-III
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